

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification<sup>5</sup> :</b> A61K 31/74, 37/02, 37/10 A61K 37/22, 39/02, 39/04 A61K 39/12	<b>A1</b>	<b>(11) International Publication Number:</b> WO 92/00081 <b>(43) International Publication Date:</b> 9 January 1992 (09.01.92)
<b>(21) International Application Number:</b> PCT/US91/04532 <b>(22) International Filing Date:</b> 25 June 1991 (25.06.91)  <b>(30) Priority data:</b> 546,585                      29 June 1990 (29.06.90)                      US  <b>(71) Applicant:</b> CHIRON CORPORATION [US/US]; 4560 Horton Street, Emeryville, CA 94608-2916 (US).  <b>(72) Inventors:</b> BARCHFELD, Gail, L. ; 404 Central Avenue, Apt. B, Alameda, CA 94501 (US). OTT, Gary ; 6625 Knobcone Street, Tahoma, CA 95733 (US). VAN NEST, Gary, A. ; 4890 San Pablo Dam Road, El Sobrante, CA 94803 (US).		<b>(74) Agents:</b> NEELEY, Richard, L. et al.; Cooley Godward Castro Huddleson & Tatum, Five Palo Alto Square, 4th Floor, Palo Alto, CA 94306 (US).  <b>(81) Designated States:</b> AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH (European patent), CI (OAPI patent), CM (OAPI patent), DE (European patent), DK (European patent), ES (European patent), FI, FR (European patent), GA (OAPI patent), GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU (European patent), MC, MG, ML (OAPI patent), MR (OAPI patent), MW, NL (European patent), NO, PL, RO, SD, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> VACCINE COMPOSITIONS CONTAINING LIPOSOMES  <b>(57) Abstract</b>  A vaccine composition, comprising an antigenic substance in association with a liposome and an oil-in-water emulsion comprising a muramyl peptide, a metabolizable oil, and optionally an additional emulsifying agent. The two components of the adjuvant (i.e., the liposome/antigen component and the emulsion component) act together to produce high levels of immune response.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

## VACCINE COMPOSITIONS CONTAINING LIPOSOMES

5

BACKGROUND OF THE INVENTIONTechnical Field

10 This invention relates generally to vaccines and is particularly directed to techniques and compositions for increasing the efficiency of vaccines and generating neutralizing antibodies.

Background

15 Liposomes are spherical vesicles consisting of a lipid bilayer and an enclosed aqueous space that are typically formed of phospholipids in aqueous solutions. By incorporating chemical or biochemical substances in the aqueous phase of the suspension in which the  
20 liposomes are formed, liposomes can be obtained that enclose within their interior space various biologically active substances. Liposomes, which typically vary in size from about 25 nm to about 1 $\mu$ m in diameter depending on how they are produced and the content of their lipid  
25 layer, therefore can be used as delivery vessels for various water-soluble substances. Since charged molecules generally do not penetrate lipid bilayers and since large molecules penetrate such layers only slowly, the liposome wall acts to insulate an organism to whom  
30 the liposomes have been administered from too rapid an effect by the enclosed material.

Liposomes have previously been used to modulate the immune response in animals by administering the liposomes with an antigen. The immune response can be  
35 modulated either for the purpose of inducing immunity in the host against a pathogen or for the purpose of producing antibodies used outside the host. For example, there is an increasing interest in improving and varying the capability of preparing antibodies to a

wide variety of determinant sites for use in immunoassays and immunodirected therapy. The unique capability of antibodies to bind to a specific determinant site or chemical structure makes them peculiarly useful in directing drugs, radioisotopes, or markers to a particular site in a host. In addition, the ability of antibodies to distinguish a specific structure from similar structures has resulted in their wide use in diagnosis.

Regardless of whether one wishes monoclonal or polyclonal antibodies for use outside the host or an immune response to protect the host against a pathogen, the initial step is the immunization of a host. As will become clear below, the composition used in immunization is referred to herein as a "vaccine" regardless of whether the composition is used to protect the host or in the production of monoclonal antibodies. Usually one hyperimmunizes the host by repeated injections of the immunogen in a vaccine composition in accordance with a predetermined schedule. Adjuvants are added to potentiate the immune response. Various adjuvants include aluminum and calcium salts, emulsifying adjuvants and bacteria, e.g., mycobacteria and corynebacteria.

When monoclonal antibodies are desired, it is particularly desirable to enhance the immune response to specific ectopic sites. Since the preparation of monoclonal antibodies requires the detection of low population events, any technique which enhances the B-lymphocyte population of interest can prove to be important in the production of monoclonal antibodies. See U.S. Patent No. 4,565,696 which describes the production of immunogens by conjugation of antigens to liposomes.

As will be described hereafter, the present invention is directed to the preparation of vaccine compositions containing liposomes. The liposomes, and various other components as will be discussed in detail

below, act as adjuvants for increasing the immunogenicity of the antigens derived from or otherwise related to pathogenic agents.

5       Currently, the only adjuvants approved for human use in the United States are aluminum salts (alum). These adjuvants have been useful for some vaccines including hepatitis B, diphtheria, polio, rabies, and influenza, but may not be useful for others, especially if stimulation of cell-mediated immunity is  
10       required for protection. Reports indicate that alum failed to improve the effectiveness of both whooping cough and typhoid vaccines and provided only a slight improvement with adenovirus vaccines. Problems with aluminum salts include induction of granulomas at the  
15       injection site and lot-to-lot variation of alum preparations.

      Complete Freund's Adjuvant (CFA) is a powerful immunostimulatory agent that has been used successfully with many antigens on an experimental basis. CFA is  
20       comprised of a mineral oil, an emulsifying agent such as Arlacel A, and killed mycobacteria such as Mycobacterium tuberculosis. Aqueous antigen solutions are mixed with these components to create a water-in-oil emulsion. CFA causes severe side effects, however, including pain,  
25       abscess formation, and fever, which prevent its use in either human or veterinary vaccines. The side effects are primarily due to the patient's reactions to the mycobacterial component of CFA.

      Incomplete Freund's Adjuvant (IFA) is similar to  
30       CFA without the bacterial component. While not approved for use in the United States, IFA has been useful for several types of vaccines in other countries. IFA has been used successfully in humans with influenza and polio vaccines and with several animal vaccines  
35       including rabies, canine distemper, and hoof-and-mouth disease. Experiments have shown that both the oil and emulsifier used in IFA can cause tumors in mice,

indicating that an alternative adjuvant would be a better choice for human use.

5 Muramyl dipeptide (MDP) represents the minimal unit of the mycobacterial cell wall complex that generates the adjuvant activity observed with CFA (see Ellouz et al. (1974) Biochem. Biophys. Res. Comm., 59: 1317). Many synthetic analogues of MDP have been generated that exhibit a wide range of adjuvant potency and side effects (reviewed in Chedid et al. (1978) Prog. Allergy, 25: 63).  
10 Three analogues that may be especially useful as vaccine adjuvants are threonyl derivatives of MDP (see Byars et al. (1987) Vaccine, 5: 223), n-butyl derivatives of MDP (see Chedid et al. (1982) Infect. and Immun., 35: 417), and lipophilic derivatives of muramyl tripeptide (see Gisler et al. (1981) Immunomodulations of Microbial Products and Related Synthetic Compounds, Y. Yamamura and S. Kotani, eds., Excerpta Medica, Amsterdam, p. 167). These compounds effectively stimulate humoral and cell-mediated immunity and exhibit low levels of toxicity.  
20

One promising lipophilic derivative of MDP is N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-[1,2-dipalmitoyl-sn-glycero-3-(hydroxyphosphoryloxy)] ethylamide (MTP-PE). This muramyl peptide has a  
25 phospholipid tail that allow association of the hydrophobic portion of the molecule with a lipid environment while the muramyl peptide portion associates with the aqueous environment. Thus the MTP-PE itself can act as an emulsifying agent to generate stable oil-in-water emulsions.  
30

In the laboratories of the inventors, using experiments on mice, MTP-PE has been shown to be effective as an adjuvant in stimulating anti-HSV gD antibody titers against Herpes simplex virus gD antigen,  
35 and that effectiveness was vastly improved if the MTP-PE and gD were delivered in oil (IFA) rather than in aqueous solution. Since IFA is not approved for human use, other oil delivery systems were investigated for

MTP-PE and antigen. An emulsion of 4% squalene with 0.008% Tween 80 and HSV gD gave very good results in the guinea pig. This formulation, MTP-PE-LO (low oil), was emulsified by passing through a hypodermic needle and was quite unstable. Nevertheless, MTP-PE-LO gave high antibody titers in the guinea pig and good protection in a HSV challenge of immunized guinea pigs (see Sanchez-Pescador et al. (1988) J. Immunology, 141: 1720-1727 and Technological Advances in Vaccine Development (1988) Lasky et al., eds., Alan R. Liss, Inc., p. 445-469). The MTP-PE-LO formulation was also effective in stimulating the immune response to the yeast-produced HIV envelope protein in guinea pigs. Both ELISA antibody titers and virus neutralizing antibody titers were stimulated to high levels with the MTP-PE formulation. However, when the same formulation was tested in large animals, such as goats and baboons, the compositions were not as effective. The desirability of additional adjuvant formulations for use with molecular antigens in humans and other large animals was evident from this lack of predictability.

Experiments of the present inventors then demonstrated that an adjuvant composition comprising a metabolizable oil and an emulsifying agent, wherein the oil and emulsifying agent are present in the form of an oil-in-water emulsion having oil droplets substantially all of which are less than 1 micron in diameter, is an effective adjuvant composition to increase the efficiency of vaccines. Investigations showed superiority of such adjuvant compositions over adjuvant compositions containing oil and emulsifying agents in which the oil droplets are significantly larger. These adjuvant compositions are the subject of a separate patent application (U.S. Application Serial No. 357,035, filed May 25, 1989).

Nevertheless, further improvement in adjuvant formulations is still desirable. For example, immunogenic compositions that lead to enhanced cellular

immune responses as well as enhanced humoral immune responses are desirable.

#### SUMMARY OF THE INVENTION

5 Accordingly, it is an object of the present invention to improve immunogenicity of vaccines, particularly subunit vaccines.

10 It is also an object of the present invention to provide vaccines in which cellular as well as humoral immune responses are activated.

15 These and other objects of the invention have been accomplished by providing a vaccine formulation comprising two components, an antigen/liposome component and an oil-in-water emulsion. The liposomes used in  
20 some embodiments are known as fusogenic liposomes, which means that they fuse with biological membranes under appropriate conditions, as discussed below. However, fusogenic liposomes are not required. Particularly useful are compositions formed using a muramyl peptide and a metabolizable oil in the form of an oil-in-water  
25 emulsion, where the oil droplets are substantially submicron size, and a separately formed liposome/antigen component that is combined with the emulsion to form the final vaccine composition.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a graph showing mean antibody titers at different times after immunization with the antigen gD2 in goats using different adjuvant formulations.

30 Figure 2 is a graph showing mean antibody titers at different times after immunization with the antigen gB2 in goats using different env2-3 adjuvant formulations.

35 Figure 3 is a graph showing mean antibody titers at different times after immunization with the antigen env203/sf2 in rhesus monkeys using different adjuvant formulations.



Figure 4 is a graph showing mean antibody titers at different times after immunization with the antigen gD2 in rabbits using different adjuvant formulations.

5 Figure 5 is a graph showing cumulative parasitemia in several groups of monkeys immunized with a malarial antigen and different adjuvants and then challenged with heterologous malaria.

10 Figure 6 is a set of two graphs showing ELISA titer (top panel) and survival (bottom panel) for mice immunized with an influenza vaccine and different adjuvants and then challenged with influenza.

#### DESCRIPTION OF SPECIFIC EMBODIMENTS

15 The individual components of vaccine compositions of the present invention are known, but they have not been combined in the present manner. In particular, it was unexpected and surprising that such vaccine compositions would enhance the efficiency of immunogens beyond the levels previously obtained when the  
20 components were used separately.

While the individual components of the vaccine composition are described herein both generally and in some detail for preferred embodiments, all the components are well known in the art, and the terms used  
25 herein, such as liposome, muramyl peptide, metabolizable oil, and emulsifying agent, are sufficiently well known to those skilled in the art to describe and identify these components.

The liposomes used in the practice of the present  
30 invention can be prepared from a wide variety of lipid materials including phosphatidyl ethers and esters, such as phosphatidylethanolamine, phosphatidylserine, and phosphatidylcholine; glycerides, such as  
dioleoylglycerosuccinate; cerebrosides; gangliosides;  
35 sphingomyelin; steroids, such as cholesterol; and other lipids. See U.S. Patent Nos. 4,235,871; 4,762,720; 4,737,323; 4,789,633; 4,861,597; and 4,873,089 for

additional description of the preparation of liposomes.

The preparation of liposomes per se is not a part of the present invention, since liposomes are well known in the prior art, as indicated by the patents listed above. In general, liposomes have been made by a number of different techniques including ethanol injection, (Batzri et al., Biochem. Biophys. Acta. 298 1015 (1973)); ether infusion, (Deamer et al., Biochem. Biophys. Acta. 443:629 (1976) and Schieren et al., Biochem. Biophys. Acta. 542:137 (1978)), detergent removal, (Razin, Biochem. Biophys. Acta. 265:241 (1972)), solvent evaporation, (Matsumato et al., J. Colloid Interface Sci. 62 149 (1977)), evaporation of organic solvents from chloroform in water emulsions (REV's), (Szoka Jr. et al., Proc. Natl. Acad. Sci. USA, 75:4194 (1978)); extrusions of MLV's or LUV's through a nucleopore polycarbonate membrane (Olson et al., Biochem. Biophys. Acta. 557 9 (1979)); and freezing and thawing of phospholipid mixtures, (Pick, Archives of Biochem. and Biophysics, 212:186 (1981)).

By convention, liposomes are categorized by size, and a 3-letter acronym is used to designate the type of liposome being discussed. Multilamellar vesicles are generally designated "MLV." Small unilamellar vesicles are designated "SUV," and large unilamellar vesicles are designated "LUV." These designations are sometimes followed by the chemical composition of the liposome. For a discussion of nomenclature and a summary of known types of liposomes, see Papahadjopoulos, Ann. N.Y. Acad. Sci., 308:1 (1978) and Ann. Repts. Med. Chem., 14:250 (1979).

A class of liposomes that has been proposed to be useful in delivering biologically active substances to cells (including substances useful as immunogens) comprises the materials known as fusogenic liposomes. These are pH-sensitive liposomes that aggregate, become destabilized, and fuse with biological membranes upon an

appropriate change in physiological conditions. Such liposomes are typically made to be pH sensitive, typically acid sensitive, to take advantage of various physiological phenomena. For example, endocytosis has been shown to be the primary route by which negatively charged liposomes are internalized by mammalian cells. Endocytosis results in the liposomes being brought into the acidic environment of an endosome or lysosome. As the environment of these organelles is acidic relative to physiological conditions in the blood stream of organisms, the change in pH can be used to release the contents of the liposomes into the cellular environment. The release of antigen directly into the cytoplasm may enable class I presentation of antigen, thereby stimulating cell mediated immune response. See U.S. Patent Nos. 4,789,633 and 4,873,089 for examples of fusogenic liposomes.

Fusogenic liposomes are generally prepared using a lipid molecule that is electrically neutral at the pH present in the blood stream of the host but which is charged at the pH present in the endosome or lysosome (typically a pH below 6.5). Examples of suitable lipids include phosphatidylethanolamine (PE) and palmitoylhomocysteine. Such fusogenic liposomes are typically composed in part of lipid molecules in which the effective cross-sectional area of the head group is smaller than the effective cross-sectional area of the hydrophobic moiety, both normal to the plane of the bilayer (i.e., PE). Further, fusogenic liposomes also contain lipid molecules capable of hydrogen bonding with the head groups of the previously described lipid molecule (e.g., oleic acid, dioleoyl glycerol succinate). When hydrogen bonding occurs, the effective surface area of the bilayer is condensed, resulting in a fusion-competent, metastable bilayer. This configuration can easily rearrange into the hexagonal II phase when closely apposed to another fusion-competent bilayer, resulting in fusion of the two membranes.

Onset of fusion can be controlled by pH, which determines the amount of interheadgroup hydrogen bonding (i.e., pH sensitive fusogenic liposomes).

Alternatively, fusion can be controlled thermally; bilayers which are fusion competent must be in the lamellar  $\alpha$  phase, or liquid crystalline state. If below  $T_m$ , they will be in the gel state, or lamellar  $\beta$  phase, and will be unable to fuse. Raising the temperature above  $T_m$  will induce fusion.

It should be emphasized, however, that fusogenic liposomes are merely one embodiment of one part of the present invention and have previously been known in many forms. As exemplary of publications describing fusogenic liposomes, see Connor et al., Proc. Natl. Acad. Sci. U.S.A. (1984) 81:1715-1718; Schneider et al., Proc. Natl. Acad. Sci. U.S.A. (1980) 77:442-446; Schenkman et al., Biochem. Biophys. Acta. (1981) 649:633-641; Schenkman et al., Chem. Phys. Lipids (1981) 28:165-180; Blumenthal et al., J. Biol. Chem. (1983) 258:349-3415; Yatvin et al., Science (1980) 210:1253-1255; Duzgunes et al., Biochemistry (1985) 24:3091-3098; Straubinger, Receptor-Mediated Targeting of Drugs (Gregoriadis, Eds.) pp. 297-315, Plenum Press New York; Straubinger et al., FEBS Lett. (1985) 179:148-154. For general information on liposomes, their properties, and methods of preparation, see Liposome Technology (Gregoriadis, ed.) CRC Press, Boca Raton, Florida (1983). For a recent general review of the use of liposomes as immunological adjuvants, including a listing of publications describing many different aspects of liposome composition, preparation, and use with antigens as immunogenic agents, see Gregoriadis, Immunology Today (1990) 11:89-97.

The present invention has been carried out with a number of liposome compositions, using both fusogenic liposomes and nonfusogenic liposomes. In these and other examples throughout the specification, the following abbreviations are used: PE, phosphatidyl

ethanolamine; GS, dioleoyl glycerol succinate; CHOL, cholesterol; OA, oleic acid; PC, phosphatidyl choline; and PS, phosphatidyl serine. One preferred fusogenic liposome composition consisted of phosphatidyl ethano-  
5 lamine and dioleoyl glycerol succinate at an 8:2 molar ratio; this composition is abbreviated PE/GS (8:2). PE/GS/CHOL (8:2:1) is also a preferred fusogenic liposome composition. Nonfusogenic liposome compositions include PC/PS (7:3) and PC/PS/CHOL (7:3:1).

10 The overall vaccine formulation of the invention contains, as previously mentioned, two principal components: the antigen/liposome component and the oil emulsion. Accordingly, the liposomes described herein are prepared in a first composition containing the  
15 antigen that is being used to induce the immune response, which is combined with the second (emulsion) component to form the composition of the invention.

The word antigen as used here refers to any substance (including a protein or protein-polysaccha-  
20 ride, protein-lipopolysaccharide, polysaccharide, lipopolysaccharide, viral subunit, or whole virus) which, when foreign to the blood stream of an animal, on gaining access to the tissue of such an animal stimulates the formation of specific antibodies and  
25 reacts specifically in vivo or in vitro with such an antibody. Moreover, the antigen stimulates the proliferation of T-lymphocytes with receptors for the antigen and can react with the lymphocytes to initiate the series of responses designated cell-mediated  
30 immunity.

A hapten is within the scope of this definition. A hapten is that portion of an antigenic molecule or antigenic complex that determines its immunological specificity. Commonly, a hapten is a peptide or  
35 polysaccharide in naturally occurring antigens. In artificial antigens it may be a low molecular weight substance such as an arsanilic acid derivative. A hapten will react specifically in vivo or in vitro with

an antibody or T-lymphocyte induced by an antigenic form of the hapten (e.g., the hapten attached to an immunogenic substance). Alternative descriptors are antigenic determinant, antigenic structural grouping and haptenic grouping.

The formulation of a vaccine of the invention will employ an effective amount of an antigen. That is, there will be included an amount of antigen which, in combination with the adjuvant, will cause the subject to produce a specific and sufficient immunological response so as to impart protection to the subject from the subsequent exposure to an virus or other pathogen.

Antigens may be produced by methods known in the art or may be purchased from commercial sources. Antigens within the scope of this invention include whole inactivated virus particles, isolated virus proteins, and protein subunits (such as those produced by genetic engineering). Vaccines of the invention may be used to immunize mammals against numerous pathogens as well as to induce antibody formation for use in diagnosis.

Examples of antigens that have been incorporated in liposome-containing compositions of the invention include a recombinant protein secreted by genetically engineered Chinese hamster ovary (CHO) cells and derived from herpes simplex virus, the recombinant protein being designated HSV rgD2. This protein has the normal anchor region truncated, giving a glycosylated protein secreted into tissue culture medium. The HSV gD2 as used in the liposomes was purified from the CHO medium to greater than 90% purity. HSV rgB2 is a fully glycosylated secreted protein produced in CHO cells similar to HSV gD2 as described above. HIV gp120 is a fully glycosylated human immunodeficiency virus protein produced in a fashion similar to that described for HSV gD2 above. HIV RT6, a recombinant form of the HIV reverse transcriptase, is produced in genetically engineered Saccharomyces cerevisiae. This protein lacks

the C terminal of the native reverse transcriptase. Both of the HIV proteins, as well as a number of different commercial influenza vaccines, have also been incorporated into liposomes for use in the practice of the present invention.

Sera 1, a recombinant form of a Plasmodium falciparum merozoite protein, is produced in genetically engineered Saccharomyces cerevisiae. This protein contains only the N-terminal 262 amino acids of the native merozoite antigen. HA Taiwan, the hemagglutinin of the influenza strain A/Taiwan/1/86 (H1N1), is cultured in hen eggs by Parke-Davis for a commercial influenza vaccine. A synthetic eleven-amino acid peptide, H-Ile-Tyr-Ser-Thr-Val-Ala-Ser-Ser-Leu-Val-Leu-OH, corresponding to a T-cell epitope identified in native HSV gB2 (Hanke, T. et al. (1991): J. of Virology 65:1177-1186), has also be used.

A number of other antigens are specifically contemplated for use with the present composition. These include HIV-env 2-3, a genetically engineered HIV protein; various malaria viruses, such as falc. 2.3; mero; sera N; and vivax 1, 2, and 3. Cytomegalovirus (CMV) proteins, including those designated as gB and gH, are also contemplated along with various hepatitis C virus (HCV) proteins. For a more detailed description of these antigens, as well as a listing of a number of publications in which these and other antigens are described in detail, see U.S. Application Serial No. 357,035, filed May 25, 1989. Also see the corresponding PCT application, Serial No. PCT/US90/02954, filed May 24, 1990, and entitled "Adjuvant Formulation Comprising a Submicron Oil Droplet Emulsion."

In general, the present invention can be used with any natural or recombinant protein or subunit protein that is suitable for vaccine development as well as with peptides comprising B-cell and T-cell epitopes. Non-

proteinaceous antigens (e.g., carbohydrates, glycolipids) can also be used.

No single dose designation can be assigned which will provide specific guidance for each and every antigen which may be employed in this invention. The effective amount of antigen will be a function of its inherent activity and purity as is understood in the art. Exemplary values are discussed below in a section describing relative amounts of the various components of the inventive composition.

The emulsion component of the present invention comprises a muramyl peptide and a metabolizable oil in an oil-in-water emulsion. The suspended oil droplets may be of any suitable size and need not be substantially submicron for use in increasing the efficiency of vaccines, although submicron oil droplets are preferred, as described below. The muramyl peptide functions as an immunostimulant in the adjuvant composition and also possesses emulsifying properties so that no separate emulsifying agent is required. Nevertheless, the emulsion component of the present invention preferably include one or more additional emulsifying agents.

Any immune-response-stimulating muramyl peptide (also known as a glycopeptide) can be used in the present invention composition. A number of preferred muramyl peptides are set forth below.

Examples of the joint emulsifying agent/immunostimulating agent are the lipophilic muramyl peptides described in the two Sanchez-Pescador et al. publications cited above. These materials comprise the basic N-acetylmuramyl peptide (a hydrophilic moiety) that acts as an immunostimulating group, but also include a lipophilic moiety that provides surface-active characteristics to the resulting compound. Such compounds, as well as other types of amphipathic immunostimulating substances, act as both immunostimulating agents and emulsifying agents and are preferred in the practice of




the present invention. In addition, it is also possible to practice the present invention by using a amphipathic immunostimulating substance in combination with a second immunostimulating substance that is not amphipathic. An example would be use of a lipophilic muramyl peptide in combination with an essentially unsubstituted (i.e., essentially hydrophilic) muramyl dipeptide.

The preferred immune-response-stimulating muramyl peptides of this invention are a group of compounds related to and generally derived from N-acetylmuramyl-L-alanyl-D-isoglutamine, which was determined by Ellouz *et al.* (1974) Biochem. & Biophys. Res. Comm., 59:1317, to be the smallest effective unit possessing immunological adjuvant activity in M. tuberculosis, the mycobacterial component of Freund's complete adjuvant. A number of dipeptide- and polypeptide-substituted muramic acid derivatives were subsequently developed and found to have immunostimulating activity.

Though these muramyl peptides are a diverse group of compounds, they can be generally represented by Formula I below:

(I)



wherein the pyran ring hydroxyl oxygens are substituted by hydrogen, alkyl, or acyl or the like, or may be replaced by nitrogen-based substituents, particularly the 6-position oxygen; the 2-amino group is an acyl group or some other amide; the lactyl side chain is modified, e.g., is ethyl or another two-position alkyl moiety; and the peptide function is a dipeptide or polypeptide, which may be further derivatized.

Furanosyl analogs of the pyranosyl compounds also have immunopotentiating activity and are useful in this invention.


Among the muramyl peptides usable in this invention are those disaccharides and tetrasaccharides linked by meso- $\alpha,\epsilon$ -diaminopimelic acid such as described in U.S. Patents 4,235,771 and 4,186,194.

5 Other immune response stimulating muramyl peptides which may be used in the practice of this invention are disclosed in U.S. Patents 4,094,971; 4,101,536; 4,153,684; 4,235,771; 4,323,559; 4,327,085; 4,185,089; 4,082,736; 4,369,178; 4,314,998; 4,082,735; and  
10 4,186,194. The disclosures of muramyl peptides in these patents are incorporated herein by reference and made a part hereof as if set out in full herein. The compounds of Japanese patent documents J5 4079-2227, J5 4079-228, and J5 41206-696 are also useful in the practice of this  
15 invention.

Methods for preparing these compounds are disclosed and well-known in the art. Preparative process exemplification can be found in U.S. Patents 4,082,736 and 4,082,735. Additionally, similar preparative  
20 processes may be found in the U.S. patents referenced in the preceding paragraph.

Preferred muramyl peptides are those having the Formula II

(II)



30 wherein

R is an unsubstituted or substituted alkyl radical containing from 1 to 22 carbon atoms, or an unsubstituted or substituted aryl radical containing from 6 to 10 carbon atoms;

35 R1 and R2 are the same or different and are hydrogen or an acyl radical containing from 1 to 22 carbon atoms;

R<sup>3</sup> is hydrogen, alkyl of 1 to 22 carbons, or aryl of 7 to 10 carbon atoms;

R<sup>4</sup> is hydrogen or alkyl of 1 to 7 carbons;

n is 0 or 1;

5 X and Z are independently alanyl, valyl, leucyl, isoleucyl, α-aminobutyryl, threonyl, methionyl, cysteinyl, glutamyl, glutaminy, isoglutaminy, aspartyl, phenylalanyl, tyrosyl, lysyl, orinithinyl, arginyl, histidyl, asparaginy, prolyl, hydroxyprolyl, seryl, or glycy;

10 R<sup>5</sup> is an optionally esterified or amidated carboxyl group of the terminal amino acid; and

Y is -NHCHR<sup>6</sup>CH<sub>2</sub>CH<sub>2</sub>CO-, wherein R<sup>6</sup> is an optionally esterified or amidated carboxyl group.

15 An optionally esterified or amidated carboxyl group is the carboxyl group itself or a carboxyl group esterified with a C<sub>1</sub>-C<sub>4</sub> alkanol, such as methanol, ethanol, propanol, butanol, or a carbamoyl group, which, on the nitrogen atom, is unsubstituted or  
20 monosubstituted or di-substituted by C<sub>1</sub>-C<sub>7</sub> alkyl, especially a C<sub>1</sub>-C<sub>4</sub> alkyl, aryl, particularly phenyl, or arylalkyl, particularly benzyl. The carbamoyl group may also be substituted with an alkylidene radical such as butylidene or pentylidene radical. In addition, the  
25 carbamoyl group R<sup>5</sup> may also be substituted with a carbamoylmethyl group on the nitrogen atom.

Particularly preferred compounds are those of Formula II wherein R and R<sup>1</sup> are the same or different and are hydrogen or an acyl radical containing from 1 to  
30 22 carbon atoms; R<sup>2</sup> is methyl; R<sup>3</sup> is hydrogen; X is L-alanyl, Y is D-isoglutaminy, and n is 0.

A different preferred group of muramyl peptides are the compounds of Formula II wherein R and R<sup>1</sup> are hydrogen or acyl of 1 to 22 carbon atoms, R<sup>2</sup> is methyl,  
35 R<sup>3</sup> is hydrogen, R<sup>4</sup> is methyl or butyl, and X is L-valyl, L-seryl, L-alanyl, L-threonyl or L-α-aminobutyryl.

Specific examples include the following compounds:

N-acetylmuramyl-L-α-aminobutyryl-D-isoglutamine;

- 6-O-stearoyl-N-acetylmuramyl-L- $\alpha$ -aminobutyryl-D-isoglutamine;  
N-acetylmuramyl-L-threonyl-D-isoglutamine;  
N-acetylmuramyl-L-valyl-D-isoglutamine;  
5 N-acetylmuramyl-L-alanyl-D-glutamine n-butyl ester;  
N-acetyl-desmethyl-D-muramyl-L-alanyl-D-isoglutamine;  
N-acetylmuramyl-L-alanyl-D-glutamine;  
N-acetylmuramyl-L-seryl-D-isoglutamine;  
10 N-acetyl(butylmuramyl)-L- $\alpha$ -aminobutyl-D-isoglutamine; and  
N-acetyl(butylmuramyl)-L-alanyl-D-isoglutamine.

An effective amount of immunostimulating muramyl peptide is that amount which effects an increase in  
15 antibody titer level when administered in conjunction with an antigen over that titer level observed when the muramyl peptide has not been co-administered. As can be appreciated, each muramyl peptide may have an effective dose range that may differ from other muramyl peptides.  
20 Therefore, a single dose range cannot be prescribed which will have a precise fit for each possible muramyl peptide within the scope of this invention. However, as a general rule, the muramyl peptide will preferably be present in the vaccine in an amount of between 0.001 and  
25 5% (w/v). A more preferred amount is 0.01 to 3% (w/v).


Most of the immunostimulating muramyl peptides discussed above are essentially hydrophilic compounds. Accordingly, they are intended for use with a separate emulsifying agent (which can be, as discussed above,  
30 also an immunostimulating agent). In some cases, the above-described compounds have a lipophilic character, such as the compounds comprising fatty acid substituents and/or aryl substituents on the sugar moiety, particularly those containing one or more acyl  
35 radicals containing from 14 to 22 carbon atoms, particularly those containing more than 1 such acyl substituent. However, it is also possible to achieve lipophilic character in a muramyl peptide by providing a

lipid moiety linked through the carboxylate group or side chains of the peptide moiety. In particular, compounds having one or more lipid groups joined to the peptide moiety through the terminal carboxylate group represent a preferred group of compounds. This linkage can readily be provided either directly, such as by forming an ester linkage between the terminal carboxylate and a fatty acid alcohol containing from 14 to 22 carbon atoms, or by using a bifunctional linking group, such as ethanolamine, to link the carboxylate through either an ester or amide linkage to a lipid. Particularly preferred in this embodiment of the invention are phospholipids, as the phosphate groups provide a readily linkable functional group.

Diacylphospho-glycerides provide one such readily linkable phospho-lipid. Phosphatidyl ethanolamine, a readily linkable, naturally occurring compound, can be easily linked to the terminal carboxylate of the peptide moiety through an amide bond. Other lipids include acylglycerols, phosphatidyl choline, phosphatidyl serine, phosphatidyl inositol, phosphatidyl glycerol, cardiolipin, and sphingomyelin.

A number of preferred amphipathic immunostimulating peptides are those having Formula III below:

(III)



wherein R, R<sup>1</sup>-R<sup>4</sup>, X, Y, Z and n have previously described meanings. L represents a lipid moiety, such as the lipid moieties described herein.

In summary, the muramic acid moiety and the peptide moiety of the molecule together provide a hydrophilic moiety. A lipophilic moiety is also present in the

molecule, lipophilicity generally being provided by a long-chain hydrocarbon group, typically present in the form of a fatty acid. The fatty acid or other hydrocarbon-containing radical can be attached to a hydroxyl group of the sugar or can be linked to the peptide portion of the molecule either directly, such as by reacting a fatty acid with a free amino group present in the peptide moiety, or through a linking group, such as a hydroxyalkylamine that forms a link between a carboxylic acid group of the peptide through amide bond formation and a functional group in a lipid, such as a phosphate group. Phospholipid moieties are particularly preferred for use in forming lipophilic muramyl peptides. A group of preferred compounds include muramyl dipeptides and tripeptides linked to a phospholipid moiety through a hydroxyalkylamine moiety. An example, and a particularly preferred compound, is N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-[1,2-dipalmitoyl-sn-glycero-3-(hydroxyphosphoryloxy)]ethylamide (abbreviated MTP-PE), manufactured by Ciba-Geigy, Ltd., Basel, Switzerland.

Another component used in the present invention is a metabolizable, non-toxic oil, preferably one of 6 to 30 carbon atoms including, but not limited to, alkanes, alkenes, alkynes, and their corresponding acids and alcohols, the ethers and esters thereof, and mixtures thereof. The oil may be any vegetable oil, fish oil, animal oil or synthetically prepared oil which can be metabolized by the body of the subject to which the adjuvant will be administered and which is not toxic to the subject. The subject is an animal, typically a mammal, and preferably a human. Mineral oil and similar toxic petroleum distillate oils are expressly excluded from this invention.

The oil component of this invention may be any long chain alkane, alkene, or alkyne, or an acid or alcohol derivative thereof either as the free acid, its salt or

an ester such as a mono-, di-, or triester, such as the triglycerides and esters of

1,2-propanediol or similar poly-hydroxy alcohols.

Alcohols may be acylated employing a mono- or poly-  
5 functional acid, for example acetic acid, propanic acid, citric acid or the like. Ethers derived from long chain alcohols which are oils and meet the other criteria set forth herein may also be used.

The individual alkane, alkene or alkyne moiety and  
10 its acid or alcohol derivatives generally will have 6-30 carbon atoms. The moiety may have a straight or branched chain structure. It may be fully saturated or have one or more double or triple bonds. Where mono or poly ester- or ether-based oils are employed, the  
15 limitation of 6-30 carbons applies to the individual fatty acid or fatty alcohol moieties, not the total carbon count.

Any metabolizable oil may be used herein, including artificial oils, but those oils derived from an animal,  
20 fish, or vegetable source are preferred. It is essential that the oil be metabolized by the host to which it is administered; otherwise the oil component may cause abscesses, granulomas or even carcinomas, or, when used in veterinary practice, may make the meat of  
25 vaccinated birds and animals unacceptable for human consumption due to the deleterious effect the unmetabolized oil may have on the consumer.

Sources for vegetable oils include nuts, seeds and grains. Peanut oil, soybean oil, coconut oil, and olive  
30 oil, the most commonly available, exemplify the nut oils. Seed oils include safflower oil, cottonseed oil, sunflower seed oil, sesame seed oil and the like. In the grain group, corn oil is the most readily available, but the oil of other cereal grains such as wheat, oats,  
35 rye, rice, teff, triticale and the like may also be used.

The technology for obtaining vegetable oils is well developed and well known. The compositions of these and

other similar oils may be found in, for example, the Merck Index and source materials on foods, nutrition and food technology.

5 The 6-10 carbon fatty acid esters of glycerol and 1,2-propanediol, while not occurring naturally in seed oils, may be prepared by hydrolysis, separation and esterification of the appropriate materials starting from the nut and seed oils. These products are commercially available under the name NEOBEE® from PVO  
10 International, Inc., Chemical Specialties Division, 416 Division Street, Boonton, NJ and others.

Oils from many animal sources may be employed in the adjuvants and vaccines of this invention. Animal  
15 oils and fats are usually solids at physiological temperatures because they are triglycerides and have a higher degree of saturation than oils from fish or vegetables. However, fatty acids are obtainable from animal fats by partial or complete triglyceride saponification which provides the free fatty acids.  
20 Fats and oils from mammalian milk are metabolizable and may therefore be used in the practice of this invention. The procedures for separation, purification, saponification and other means necessary for obtaining pure oils from animal sources are well known in the art.

25 Most fish contain metabolizable oils which may be readily recovered. For example, cod liver oil, shark liver oils, and whale oil such as spermaceti exemplify several of the fish oils which may be used herein. A number of branched chain oils are synthesized biochemi-  
30 cally in 5-carbon isoprene units and are generally referred to as terpenoids. Shark liver oil contains a branched, unsaturated terpenoids known as squalene, 2,6,10,15,19,23-hexamethyl-2,6,10,14,18,22-tetracosahexaene, which is particularly preferred  
35 herein. Squalane, the saturated analog to squalene, is also a particularly preferred oil. Fish oils, including squalane and squalene, are readily available from



commercial sources or may be obtained by methods known in the art.

5 The oil component of these adjuvants and vaccine formulations will be present in an amount from 0.5% to 15% by volume preferably in an amount of 1% to 12%. It is most preferred to use from 1% to 4% oil.

10 The aqueous portion of these adjuvant compositions is generally buffered saline or, in some preferred embodiments, unadulterated water. Because these compositions are intended for parenteral administration, it is preferable to make up final buffered solutions used as vaccines so that the tonicity, i.e.,  
15 osmolality, is essentially the same as that of normal physiological fluids in order to prevent post-administration swelling or rapid absorption of the composition because of differential ion concentrations between the composition and physiological fluids. It is also preferable to buffer the saline in order to maintain a pH compatible with normal physiological  
20 conditions. Also, in certain instances, it may be necessary to maintain the pH at a particular level in order to insure the stability of certain composition components such as the glycopeptides.

25 Any physiologically acceptable buffer may be used herein, but phosphate buffers are preferred. Other acceptable buffers such as citrate, acetate, tris, bicarbonate, carbonate, or the like may be used as substitutes for phosphate buffers. The pH of the aqueous component will preferably be between 6.0 and  
30 8.0.

35 However, if the adjuvant is prepared as a submicron oil-in-water emulsion, unadulterated water is preferred as the aqueous component of the emulsion during emulsion formation. Increasing the salt concentration makes it more difficult to achieve the desired small droplet size. When the final vaccine formulation is prepared from the adjuvant, the antigenic material can be added

in a buffer at an appropriate osmolality to provide the desired vaccine composition.

The quantity of the aqueous component employed in these compositions will be that amount necessary to bring the value of the composition to unity. That is, a quantity of aqueous component sufficient to make 100% will be mixed with the other components listed above in order to bring the compositions to volume.

A substantial number of emulsifying and suspending agents are generally used in the pharmaceutical sciences. These include naturally derived materials such as gums from trees, vegetable protein, sugar-based polymers such as alginates and cellulose, and the like. Certain oxypolymers or polymers having a hydroxide or other hydrophilic substituent on the carbon backbone have surfactant activity, for example, povidone, polyvinyl alcohol, and glycol ether-based mono- and poly-functional compounds. Long-chain-fatty-acid-derived compounds form a third substantial group of emulsifying and suspending agents which could be used in this invention. Any of the foregoing surfactants are useful so long as they are non-toxic.

Specific examples of suitable emulsifying agents (also referred to as surfactants or detergents) which can be used in accordance with the present invention include the following:

1. Water-soluble soaps, such as the sodium, potassium, ammonium and alkanol-ammonium salts of higher fatty acids (C<sub>10</sub>-C<sub>22</sub>), and, particularly sodium and potassium tallow and coconut soaps.

2. Anionic synthetic non-soap detergents, which can be represented by the water-soluble salts of organic sulfuric acid reaction products having in their molecular structure an alkyl radical containing from about 8 to 22 carbon atoms and a radical selected from the group consisting of sulfonic acid and sulfuric acid ester radicals. Examples of these are the sodium or potassium alkyl sulfates, derived from tallow or coconut

oil; sodium or potassium alkyl benzene sulfonates; sodium alkyl glyceryl ether sulfonates; sodium coconut oil fatty acid monoglyceride sulfonates and sulfates; sodium or potassium salts of sulfuric acid esters of the reaction product of one mole or a higher fatty alcohol and about 1 to 6 moles of ethylene oxide; sodium or potassium alkyl phenol ethylene oxide ether sulfonates, with 1 to 10 units of ethylene oxide per molecule and in which the alkyl radicals contain from 8 to 12 carbon atoms; the reaction product of fatty acids esterified with isethionic acid and neutralized with sodium hydroxide; sodium or potassium salts of a fatty acid amide of a methyl tauride; and sodium and potassium salts of SO<sub>3</sub>-sulfonated C<sub>10</sub>-C<sub>24</sub>  $\alpha$ -olefins.

3. Nonionic synthetic detergents made by the condensation of alkylene oxide groups with an organic hydrophobic compound. Typical hydrophobic groups include condensation products of propylene oxide with propylene glycol, alkyl phenols, condensation products of propylene oxide and ethylene diamine, aliphatic alcohols having 8 to 22 carbon atoms, and amides of fatty acids.

4. Nonionic detergents, such as amine oxides, phosphine oxides and sulfoxides, having semipolar characteristics. Specific examples of long chain tertiary amine oxides include dimethyldodecylamine oxide and bis-(2-hydroxyethyl) dodecylamine. Specific examples of phosphine oxides are found in U.S. Patent No. 3,304,263 which issued February 15, 1967, and include dimethyldodecylphosphine oxide and dimethyl-(2-hydroxydodecyl) phosphine oxide.

5. Long chain sulfoxides, including those corresponding to the formula R<sub>1</sub>-SO-R<sub>2</sub> wherein R<sub>1</sub> and R<sub>2</sub> are substituted or unsubstituted alkyl radicals, the former containing from about 10 to about 28 carbon atoms, whereas R<sub>2</sub> contains from 1 to 3 carbon atoms. Specific examples of these sulfoxides include dodecyl

methyl sulfoxide and 3-hydroxy tridecyl methyl sulfoxide.

5 6. Ampholytic synthetic detergents, such as sodium 3-dodecylaminopropionate and sodium 3-dodecylaminopropane sulfonate.

7. Zwitterionic synthetic detergents, such as 3-(N,N-dimethyl-N-hexadecylammonio) propane-1-sulfonate and 3-(N,N-dimethyl-N-hexadecylammonio)-2-hydroxy-propane-1-sulfonate.

10 Additionally, all of the following types of emulsifying agents can be used in a composition of the present invention: (a) soaps (i.e., alkali salts) of fatty acids, rosin acids, and tall oil; (b) alkyl arene sulfonates; (c) alkyl sulfates, including surfactants  
15 with both branched-chain and straight-chain hydrophobic groups, as well as primary and secondary sulfate groups; (d) sulfates and sulfonates containing an intermediate linkage between the hydrophobic and hydrophilic groups, such as the fatty acylated methyl taurides and the  
20 sulfated fatty monoglycerides; (e) long-chain acid esters of polyethylene glycol, especially the tall oil esters; (f) polyethylene glycol ethers of alkylphenols; (g) polyethylene glycol ethers of long-chain alcohols and mercaptans; (h) fatty acyl diethanol amides; and (i)  
25 block copolymers of ethylene oxide and propylene oxide. Since surfactants can be classified in more than one manner, a number of classes of surfactants set forth in this paragraph overlap with previously described surfactant classes.

30 There are a number of emulsifying agents specifically designed for and commonly used in biological situations. For example, a number of biological detergents (surfactants) are listed as such by Sigma Chemical Company on pages 310-316 of its 1987  
35 Catalog of Biochemical and Organic Compounds. Such surfactants are divided into four basic types: anionic, cationic, zwitterionic, and nonionic. Examples of anionic detergents include alginic acid, caprylic acid,

cholic acid, 1-decanesulfonic acid, deoxycholic acid, 1-dodecanesulfonic acid, N-lauroylsarcosine, and taurocholic acid. Cationic detergents include dodecyltrimethylammonium bromide, benzalkonium chloride, 5 benzyldimethylhexadecyl ammonium chloride, cetylpyridinium chloride, methylbenzethonium chloride, and 4-picoline dodecyl sulfate. Examples of zwitterionic detergents include 3-[(3-cholamidopropyl)-dimethylammonio]-1-propanesulfonate 10 (commonly abbreviated CHAPS), 3-[(cholamidopropyl)-dimethylammonio]-2-hydroxy-1-propanesulfonate (generally abbreviated CHAPSO), N-dodecyl-N,N-dimethyl-3-ammonio-1-propanesulfonate, and lyso- $\alpha$ -phosphatidylcholine. Examples of nonionic detergents include decanoyl-N- 15 methylglucamide, diethylene glycol monopentyl ether, n-dodecyl  $\beta$ -D-glucopyranoside, ethylene oxide condensates of fatty alcohols (e.g., sold under the trade name Lubrol), polyoxyethylene ethers of fatty acids (particularly C<sub>12</sub>-C<sub>20</sub> fatty acids), polyoxyethylene 20 sorbitan fatty acid ethers (e.g., sold under the trade name Tween), and sorbitan fatty acid ethers (e.g., sold under the trade name Span).

A particularly useful group of surfactants are the sorbitan-based non-ionic surfactants. These surfactants 25 are prepared by dehydration of sorbitol to give 1,4-sorbitan which is then reacted with one or more equivalents of a fatty acid. The fatty-acid-substituted moiety may be further reacted with ethylene oxide to give a second group of surfactants.

30 The fatty-acid-substituted sorbitan surfactants are made by reacting 1,4-sorbitan with a fatty acid such as lauric acid, palmitic acid, stearic acid, oleic acid, or a similar long chain fatty acid to give the 1,4-sorbitan mono-ester, 1,4-sorbitan sesquiesther or 1,4-sorbitan 35 triester. The common names for these surfactants include, for example, sorbitan monolaurate, sorbitan monopalmitate, sorbitan monestearate, sorbitan monooleate, sorbitan

sesquioleate, and sorbitan trioleate. These surfactants are commercially available under the name SPAN® or ARLACEL®, usually with a letter of number designation which distinguishes between the various mono, di- and triester substituted sorbitans.

SPAN® and ARLACEL® surfactants are hydrophilic and are generally soluble or dispersible in oil. They are also soluble in most organic solvents. In water they are generally insoluble but dispersible. Generally these surfactants will have hydrophilic-lipophilic balance (HLB) number between 1.8 and 8.6. Such surfactants can be readily made by means known in the art or are commercially available from, for example, ICI America's Inc., Wilmington, DE under the registered mark ATLAS®.

A related group of surfactants comprises polyoxyethylene sorbitan monoesters and polyoxyethylene sorbitan triesters. These materials are prepared by addition of ethylene oxide to a 1,4-sorbitan monoester or triester. The addition of polyoxyethylene converts the lipophilic sorbitan mono- or triester surfactant to a hydrophilic surfactant generally soluble or dispersible in water and soluble to varying degrees in organic liquids.

These materials, commercially available under the mark TWEEN®, are useful for preparing oil-in-water emulsions and dispersions, or for the solubilization of oils and making anhydrous ointments water-soluble or washable. The TWEEN® surfactants may be combined with a related sorbitan monoester or triester surfactants to promote emulsion stability. TWEEN® surfactants are commercially available from a number of manufacturers, for example ICI America's Inc., Wilmington, DE under the registered mark ATLAS® surfactants.

A third group of non-ionic surfactants which could be used alone or in conjunction with SPAN®, ARLACEL® and TWEEN® surfactants are the polyoxyethylene fatty acids made by the reaction of ethylene oxide with a long-chain

fatty acid. The most commonly available surfactant of this type is sold under the name MYRJ® and is a polyoxyethylene derivative of stearic acid. MYRJ® surfactants are hydrophilic and soluble or dispersible in water like TWEEN® surfactants. The MYRJ® surfactants may be blended with TWEEN® surfactants or with TWEEN®/SPAN® or ARLACEL® surfactant mixtures for use in forming emulsions. MYRJ® surfactants can be made by methods known in the art or are available commercially from ICI America's Inc.

A fourth group of polyoxyethylene-based non-ionic surfactants are the polyoxyethylene fatty acid ethers derived from lauryl, acetyl, stearyl and oleyl alcohols. These materials are prepared as above by addition of ethylene oxide to a fatty alcohol. The commercial name for these surfactants is BRIJ®. BRIJ® surfactants may be hydrophilic or lipophilic depending on the size of the polyoxyethylene moiety in the surfactant. While the preparation of these compounds is available from the art, they are also readily available from such commercial sources as ICI America's Inc.

Other non-ionic surfactants which could potentially be used in the practice of this invention include polyoxyethylene, polyol fatty acid esters, polyoxyethylene ether, polyoxypropylene fatty ethers, bee's wax derivatives containing polyoxyethylene, polyoxyethylene lanolin derivative, polyoxyethylene fatty acid glycerides, and glycerol fatty acid esters or other polyoxyethylene acid alcohol or ether derivatives of long-chain fatty acids of 12-22 carbon atoms.

As the adjuvant and the vaccine formulations of this invention are intended to be multi-phase systems, it is preferable to choose an emulsion-forming non-ionic surfactant which has an HLB value in the range of about 7 to 16. This value may be obtained through the use of a single non-ionic surfactant such as a TWEEN® surfactant or may be achieved by the use of a blend of surfactants such as with a sorbitan mono-, di- or

triester based surfactant; a sorbitan ester-  
polyoxyethylene fatty acid; a sorbitan ester in  
combination with a polyoxyethylene lanolin derived  
surfactant; a sorbitan ester surfactant in combination  
5 with a high HLB polyoxyethylene fatty ether surfactant;  
or a polyethylene fatty ether surfactant or  
polyoxyethylene sorbitan fatty acid.

It is more preferred to use single non-ionic  
surfactant, most particularly a TWEEN® surfactant, as  
10 the emulsion stabilizing non-ionic surfactant in the  
practice of this invention. The surfactant named TWEEN®  
80, otherwise known as polysorbate 80 or polyoxyethylene  
20 sorbitan monooleate, is the most preferred of the  
foregoing surfactants.

15 Suitable oil-in-water emulsions can usually be  
effected by having the surfactant present in an amount  
of 0.02% to 2.5% by weight (w/w). An amount of 0.05% to  
1% is preferred with 0.01 to 0.5% being especially  
preferred.

20 The manner in which oil-in-water emulsion of the  
invention is reached is not important to the practice of  
the present invention. One manner in which such an  
emulsion can be obtained is by use of a commercial  
emulsifiers, such as model number 110Y available from  
25 Microfluidics, Newton, MA. Examples of other commercial  
emulsifiers include Gaulin Model 30CD (Gaulin, Inc.,  
Everett, MA) and Rainnie Minlab Type 8.30H (Micro  
Atomizer Food and Dairy, Inc., Hudson, WI). These  
emulsifiers operate by the principle of high shear  
30 forces developed by forcing fluids through small  
apertures under high pressure. While the use of the  
present invention does not preclude use of such  
emulsifiers, their use is not necessary, nor preferred,  
to practice the present invention. If submicron oil  
35 droplets are not desired, other apparatuses that develop  
lower shear forces can be used (including simple passage  
of formulations through a syringe needle).



The size of the oil droplets can be varied by changing the ratio of detergent to oil (increasing the ratio decreases droplet size), operating pressure (increasing operating pressure decreases droplet size),  
5 temperature (increasing temperature decreases droplet size), and adding an amphipathic immunostimulating agent (adding such agents decreases droplet size). Actual droplet size will vary with the particular detergent, oil, and immunostimulating agent (if any) and with the  
10 particular operating conditions selected. Droplet size can be verified by use of sizing instruments, such as the commercial Sub-Micron Particle Analyzer (Model N4MD) manufactured by the Coulter Corporation.

The emulsion components are prepared from the  
15 ingredients described above prior to combining with the liposome/antigen component that will be used in the vaccine. The liposomes cannot be prepared in the presence of the emulsion components, because the phospholipids and other components of the liposomes  
20 would simply be incorporated into the emulsion and function as emulsifiers.

Since the emulsion component of the invention is stable, the liposome/antigen and emulsion can be combined by simple mixing, stirring, or shaking. Other  
25 techniques, such as passing a mixture of the two components rapidly through a small opening (such as a hypodermic needle) readily provides a useful vaccine composition.

The various components of the composition of the  
30 present invention can be present in a wide range of ratios. The liposome/antigen and emulsion components are typically used in a volume ratio of 1:10 to 10:1. Volume ratios of from 1:3 to 3:1 are preferred, with volume ratios of about 1:1 being preferred, as they are  
35 easy to prepare and readily discernable. However, other ratios may be more appropriate for specific purposes, such as when a particular antigen is both difficult to incorporate into a liposome and has a low

immunogenicity, in which case a higher relative amount of the antigen component is required.

Liposomes are generally prepared at about 1 to 100 mg lipid per ml of lipid suspension for a final concentration of about 0.5 to 50 mg lipid per ml. More preferred are liposomes prepared at about 3 to 30 mg lipid per ml, more preferably about 10 mg lipid per ml.

Antigen masses are generally selected based on the desired dose and the volume of the final composition that will be injected. For example, if 10 micrograms of an antigen is known to induce the desired immunogenic response and if 1 milliliter is the normal injected amount for the animal being immunized, a vaccine composition will be prepared using the guidelines set forth herein so that 1 milliliter of the final vaccine composition contains 10 micrograms of the antigen. Antigens are typically administered at concentrations of about 1 to 500  $\mu\text{g/ml}$ , more commonly 10 to 50  $\mu\text{g/ml}$ . However, these are only general guidelines and the specific amount of antigen must be adjusted depending on the immunogenic response as previously discussed.

In a similar manner, the amount of muramyl tripeptide (if used) is adjusted to provide a standard dose and the final vaccine composition. Such standard doses are typically in the range of from about 1 to about 2500  $\mu\text{g/ml}$ , preferably about 10 to 250  $\mu\text{g/ml}$ .

To ensure mixing with the emulsion, the size is generally selected to match the emulsion particle size. For example, liposomes in the range of from 200 to 450 nM in diameter have prepared for use in submicron emulsions. Unilamellar liposomes are particularly preferred.

Although at least some of the antigen is associated with the liposomes by being incorporated therein or by being associated with the liposome surface, is also possible to have compositions of the invention in which antigen is present that is not associated with the

liposomes. This antigen can be present in the emulsion when the emulsion is initially prepared, or the antigen can become disassociated from the liposome composition, which will typically contain some liquid phase associated with and external to the liposomes.

The invention now being generally described, the same will be better understood by reference to the following detailed examples which are provided by way of illustration and are not intended to be limiting of the invention unless so specified.

#### EXAMPLES

##### Example 1: Physical Association of gD2 with Liposomes

Studies were carried out to demonstrate the association of antigen with liposomes, a prerequisite to delivery of antigen by liposomes to cells.

##### Nonfusogenic

Liposomes composed of PC/PS (7:3) were prepared both by octyl glucoside dialysis and by reverse phase evaporation (REV). gD2 at 100 µg/ml was tracked using stable iodinated gD2 as a marker. Separation of liposomes from unassociated gD2 by liquid chromatography demonstrated that 17% of gD2 associated with dialysis liposomes, and REV liposomes had 33% gD2 associated. None of the liposomes associated with gD2 was susceptible to trypsin digestion, indicating that gD2 was not present on the outer surface of the vesicles. Incubating the liposomes (2 mM lipid) overnight with 0.4 to 2 mM Triton® X-100 resulted in progressive dissociation of gD2 at higher levels of Triton®, consistent with progressive permeabilization of the liposomes. The REV liposomes were somewhat more resistant to detergent permeabilization due to the lack of residual octyl glucoside with this method.

##### Fusogenic

Liposomes composed of PE/GS (8:2) were prepared by octyl glucoside dialysis. Since this lipid composition was incompatible with the REV technique, we used PE/OA (8:2) for that method of preparation. The substitution of oleic acid for glycerol-succinate produces stable LUV by REV. Dialysis liposomes had 39% associated gD2 and REV liposomes had 72% association (Table 1). Of the associated gD2, about 50% was removed from dialysis liposomes by trypsin digestion and therefore was externally accessible. Fusogenic dialysis liposomes were more readily permeabilized by Triton® than the nonfusogenic formulation. The REV liposomes containing oleic acid lost most labeled gD2 when treated with either trypsin or Triton®. Rather than providing useful information regarding gD2 association with these vesicles, this demonstrates the intrinsic leakiness of a vesicle preparation containing 20 mole percent fatty acid.

Incubation of gD2 with pre-formed PE/GS/CHOL (8:2:2) dialysis liposomes resulted in zero association of gD2 with liposomes.

TABLE 1  
GD2 Association with Liposomes

<u>Lipid Composition</u>	<u>Method of Preparation</u>	<u>GD2 % Association</u>	<u>Trypsin Digestion</u>	<u>Triton X-100 Permeabilization</u>
PC/PS (7:3)	octyl glucoside dialysis	17	-	++
	reverse phase evaporation	33	-	+
PE/GS (8:2)	octyl glucoside dialysis	39	++	+++
PE/OA (8:2)	reverse phase evaporation	72	++++	++++
- = no loss of GD2 from liposomes + = release of GD2 with 0.1% Triton ++ = GD2 removed from liposomes by 0.05% Triton +++ = GD2 removed by 0.025% ++++ = total release of GD2 from liposomes by 0.025% Triton				

Example 2: Physical Association of RT6 With Liposomes

5 In a manner similar to that described in Example 1, the association of the genetically engineered HIV reverse transcriptase molecule RT6 with liposomes was measured. RT6 associates at 29% with PC/PS (7:3) dialysis liposomes and 73% with PE/GS (8:2) dialysis liposomes. Low iodine labeling of the RT6 resulted in equivocal trypsin digestion and Triton®  
10 permeabilization effects.

Example 3: Physical Association of gp120 With Liposomes

15 In a similar manner, the association of HIV gp120 with PC/PS (7:3) dialysis liposomes was determined to be 8% and with PE/GS (8:2) dialysis liposomes, 11%, much lower than the association levels observed for gD2 and RT6. Gel filtration HPLC chromatograms reveal the presence of a gp120-rich peak which lies  
20 between the liposome fraction and monomeric gp120. The peak is probably mixed micelles of gp120 and octylglucoside. Trypsin digestion and Triton® permeabilization indicate the gp120 is encapsulated in both liposome preparations and is not externally  
25 accessible in either.

The association of gp120 with fusogenic liposomes was enhanced by preparing liposomes by the freeze-thaw-filter method. Association of antigen was determined by protein analysis of pelleted liposomes.

30 Incubation of gp120 with pre-formed freeze-thaw-filtered (FTF) liposomes of either PC/PS (7:3) or PE/GS/CHOL (8:2:2) composition resulted in zero association.

TABLE 2  
gp120 Association with Liposomes

<u>Lipid Composition</u>	<u>Method of Preparation</u>	<u>gp120 % Association</u>	<u>Trypsin Digestion</u>	<u>Triton X-100 Permeabilization</u>
PC/PS (7:3)	octyl glucoside dialysis	8	-	++
PE/GS (8:2)	octyl glucoside dialysis	11	-	++
PE/GS/CHOL (8:2:1)	freeze-thaw-filter	56	ND	ND

- = no loss of gp120 from liposomes  
 ++ = gp120 removed from liposomes by 0.1% Triton  
 ND = not determined

Example 4: Association of Malaria Sera 1 with Liposomes

5 The association of malaria sera 1 protein with PC/PS (7:3) liposomes was 67% with dialysis liposomes and 95% with FTF liposomes. Sera 1 added to pre-formed liposomes associated 75% with FTF vesicles. Sera 1 association with PE/GS/CHOL (8:2:2) liposomes was 65% with dialysis liposomes and 87% with FTF liposomes. 10 Sera 1 associated at 91% with pre-formed dialysis liposomes. Unbound protein was separated from liposomes by centrifugation. Antigen association was determined by protein assay of liposome pellets.

15 Example 5: Physical Association of Influenza HA Taiwan with Liposome

HA Taiwan associated at 69% with DPPC/DMPG (8:2) dialysis liposomes. HA Taiwan associated at 78% with PE/GS/CHOL (8:2:2) dialysis liposomes and at 80% with 20 pre-formed vesicles. Association was measured as described for Sera 1.

Example 6: Physical Association of HSV gB2 Peptide with Liposomes

25 HSV gB2 peptide associated at 40% with PC/PS (7:3) FTF liposomes, determined as described for Sera 1.

Example 7: Physical Association of gB2 with Liposomes

30 HSB gB2 associated at 24% with PE/GS/CHOL (8:2:2) liposomes prepared by dialysis. The association of gB2 is 84% when the liposomes are prepared by FTF. Protein association was determined by removing unbound gB2 by centrifugation and measuring gB2 35 associated with the liposome pellet by capture ELISA.-



Example 8: In Vitro Studies on Antigen Uptake and Cellular Localization

5 Studies were undertaken to determine the intracellular fate of antigen using the compositions of the invention.

Initial experiments to demonstrate uptake of FITC-dextran loaded liposomes by murine and human macrophages have been consistently successful.

10 Liposomes prepared by reverse phase evaporation and by high pressure extrusion are taken up equally well. Nonfusogenic lipid compositions used were PC/PS at a mole ratio of 7:3 and PC/phosphatidylglycerol at 9:1. Fusogenic lipid compositions were either PE/CHOL/OA at

15 4:4:2 or PE/OA at 8:2. To form fusogenic liposomes, the aqueous phase is initially at pH 10. Upon exchange of the external volume by gel filtration at pH 7.4, the liposomes are stable for at least two days, based on phase contrast and epifluorescence

20 microscopy.

An eighteen hour pulse of nonfusogenic liposomes with macrophages produces bright punctate fluorescence inside the cells. Pulse chase experiments demonstrate that liposomes are first present at the periphery of

25 the cytosol, then move to the perinuclear region. This is consistent with endosomal uptake followed by intracellular transport to lysosomes. Incorporation of MTP-PE into the bilayer at the lipid:MTP-PE mole ratio of 250:1 had no effect on uptake kinetics.

30 Similar experiments done with fusogenic liposomes resulted in a combination of bright punctate fluorescence and dim diffuse fluorescence. Pulse chase experiments did not entirely eliminate the punctate fluorescence, suggesting that endosomal

35 fusion is less than 100% efficient. Furthermore, liposome titration experiments show that fusion can be overwhelmed: greater than  $100 \mu\text{g phospholipid}/10^4$  cells/cm<sup>2</sup> produced heavily loaded punctate

fluorescence with some diffuse fluorescence, whereas less than 10  $\mu\text{g}$  phospholipid/ $10^4$  cells/ $\text{cm}^2$  produced predominantly diffuse fluorescence. Incorporation of MTP-PE at phospholipid:MTP-PE mole ratios of 1000:1, 500:1, and 250:1 resulted in extremely faint levels of both diffuse and punctate fluorescence, with the effect most marked below 1000:1. Free FITC-dextran was not endocytosed under these conditions, strongly suggesting that the shutdown of endocytosis is not a surface effect, but rather a result of MTP-PE entering the cytosol. Preliminary experiments with FITC-gD2 loaded liposomes indicate that gD2 is readily delivered into macrophages by this method.

#### 15    Example 9: Macrophage Uptake

We compared the uptake of FITC-dextran-loaded liposomes by U937 cells, a human monocyte-like cell line from American Type Culture Collection, to our previous uptake experiments with primary macrophage cultures. Undifferentiated U937 cells did not phagocytose either liposomes or free FITC-dextran. If the cells were differentiated with phorbol-myristic-acetate and incubated 18 hours with nonfusogenic PC/PG (8:2) liposomes, they acquired punctate fluorescence indicating uptake of the dextran into endosomes or lysosomes. Incubation with fusogenic PE/GS (8:2) liposomes produced uniform diffuse fluorescence indicating delivery of the dextran to the cell cytoplasm. Incorporation of MTP-PE in the liposomes did not affect phagocytosis. While these results are similar to those observed in true macrophages, a major difference between the two cell types is in rate of uptake: differentiated U937 cells require about ten times as much lipid as macrophages to acquire visible amounts of fluorescence. For macrophages, phagocytosis itself is an activation signal. U937 cells may not be activated by phagocytosis.

U937 cells matured with 25 ng/ml PMA for 5 days were incubated overnight with soluble gD2, nonfusogenic PC liposomes with gD2, and fusogenic PE liposomes with gD2. The presence of intracellular gD2 was assessed by immunofluorescence of FITC-goat- $\alpha$  mouse Ab bound to mouse- $\alpha$  gD Mab.

We found that soluble gD2 resulted in lower levels of fluorescence than either liposome preparation, and that PE liposomes produced higher fluorescence levels than PC liposomes. Overall, the same pattern of uptake was observed whether the cells were incubated in the presence or absence of 10% serum, with fluorescence being somewhat higher in the presence of serum. Cells incubated with soluble gD2 had low levels of diffuse fluorescence. Cells incubated with either liposome preparation had predominantly diffuse fluorescence with occasional punctate fluorescence. These results are in contrast to our earlier experiment with FITC-dextran-loaded liposomes in which diffuse fluorescence was associated with fusogenic liposomes and punctate fluorescence was observed with nonfusogenic liposomes. Since gD2 is a pH-insensitive fusogenic protein, it may be inducing fusion of both types of liposomes with the cells, which would produce diffuse fluorescence.

The experiments above suggested that gD2 may alter the intracellular localization of liposome contents. To test this, U937 cells were incubated overnight with liposomes prepared with either gD2 and FITC-dextran or gD2 and RT6. Epifluorescence microscopy showed that PC/PS liposomes produced a punctate pattern of fluorescence for both FITC-dextran and RT6. In the case of PE/GS liposomes, diffuse fluorescence was observed for both FITC-dextran and RT6. Under these conditions, gD2 is not able to alter the localization of liposome contents.

Example 10: Immunogenicity of Liposome/Emulsion  
Combinations with gD2 in goats

5        These data show that for a given emulsion, higher  
antibody titers are obtained if the antigen is com-  
bined with liposomes prior to mixing with emulsion.  
The antibody titers elicited by either fusogenic or  
nonfusogenic liposomes are approximately equivalent  
when mixed with emulsions.

10        In an this experiment, a composition consisting  
of an oil-in-water emulsion containing MTP-PE,  
designated MF79/1501 (10% squalene (v/v); 1% Tween ®  
80 (v/v); 5% Tetronic® 1501 (a polyoxyethylene-  
polyoxypropylene block polymer) (v/v); 400 µg/ml MTP-  
15        PE), combined with the gD2 antigen was tested for  
immunogenicity. This composition was then compared to  
the combination of MF79/1501 plus fusogenic liposomes.  
This liposome-gD2 mixture was used to immunize animals  
three times at three-week intervals. As seen in Table  
20        3, this combined emulsion-liposome immunization gave  
high antibody responses. After two immunizations the  
liposome plus emulsion group showed a mean titer of  
7258, approximately three-fold higher than the  
M79/1501 emulsion alone. This response was very  
consistent within the group with a standard error of  
25        only 10%. After the third immunization, all animals  
in the group showed moderate increases in titer except  
one. Thus combining liposomes with emulsions offered  
significant increases in immune response.

30

TABLE 3  
GD2 Adjuvant Study in Goats

Animal Number	Adjuvant	Pre-bleed	Mean <sup>a</sup> ELISA Titer for Bleeds		
			1/2 <sup>b</sup>	2/2	3/2
5026	2x MF59 (Internal control)*	(<5)	37	448	800
5035		(<5)	385	802	741
6156		(<5)	40	191	450
6511		(<5)	<5	887	617
6629		(<5)	144	941	576
			53+39	564+170	624+63
5031	MF79/1501	(<5)	3,277	4,456	8,766
6153		(<5)	125	870	5,189
6165		(<5)	96	1,173	1,204
6517		(<5)	784	3,830	10,706
6626		(<5)	40	4,009	4,113
			262+209	2,338+810	4,747+1,823
5033	MF79/1501 + Liposomes	(<5)	598	7,381	10,633
6155		(<5)	869	5,878	8,683
6510		(<5)	846	10,517	14,995
6519		(<5)	279	6,354	13,079
6628		(<5)	235	6,945	1,845
			492+136	7,258+729	8,039+3,041

<sup>a</sup>Geometric mean + standard error.

<sup>b</sup>Bleed identification: Number of immunizations/weeks post immunization.

\* 2x MF59 = 10% squalene (v/v); 0.4% Tween 80 (v/v); 1.6% Span 85 (v/v); 400 mg/ml MTP-PE

Example 12: Effects of gD2 Association with Liposomes  
on the Immunogenicity of Liposome/Emulsion  
Combinations in Goats

5        In this experiment goats were immunized 3 times  
with 25  $\mu$ g gD2 and 100  $\mu$ g MTP-PE at four-week inter-  
vals with one of the following adjuvants:  
1, MF79/121 (10% squalene, 1% Tween 80, 5% Pluronic  
10 L121, 400  $\mu$ g/ml MTP-PE); 2, MF79/121 combined with LPC  
(PC/PS (7:3) dialysis liposomes), such that 50% of the  
gD2 was associated with the liposomes and 50% of the  
gD2 was free in the aqueous phase of the formulation;  
3, MF79/L121 combined with the LPC such that 100% of  
15 the gD2 was associated with the liposomes. As shown  
in Figure 1, an increase in antibody titers is  
correlated with increased antigen association with  
liposomes. Geometric mean antibody titers for groups  
of 5 animals are given in Table 5. Enhanced Ab titers  
20 persisted for at least six weeks after a fourth  
immunization.

TABLE 4  
gD2 Adjuvant Study in Goats

Adjuvant	Prebleed	Mean ELISA Titer for Bleeds		
		1/2	2/2	3/2
2x MF59	<5	<5	144+85	837+169
2x MF59 + Liposomes (PE/GS)	<5	<5	344+187	1440+842
MF79/1501 + Liposomes (PE/GS)	<5	<5	1000+328	4653+616
Alum	<5	<5	39+24	<5
MF79/1501 + Liposomes (PC/PS)	<5	58+61	1980+416	6946+1503
Liposomes (PE/GS) + MTP exogenous	<5	<5	6+1	6+1

Example 11: Effects of Emulsion/Liposome Combinations  
With gD2 in Goats on Antibody Titers

In this experiment, goats were immunized with gD2  
(25  $\mu$ g) combined with several emulsions, liposome/  
emulsion combinations, and liposomes alone. Liposome/  
emulsion combinations tested were PE/GS liposomes plus  
2x MF59, PE/GS liposomes plus MF79/5% Tetronic® 1501,  
and PC/PS liposomes plus MF79/5% Tetronic® 1501.  
Controls in this experiment included alum, and 2x  
MF59. All MTP-PE doses were 100  $\mu$ g. With liposome  
emulsion combinations approximately 50% of the antigen  
was entrapped in liposomes and 50% was free in solu-  
tion. All MTP-PE was in the emulsion phase in lipo-  
some/emulsion combinations. In the liposome alone  
group, MTP-PE was added exogenously to the liposomes.  
Animals were immunized three times at three-week  
intervals and anti-gD2 antibody titers were determined  
14 days after each immunization (results are shown in  
Table 4).

Combinations of MF79/5% 1501 and PE/GS liposomes  
(fusogenic LUV) gave much higher anti-gD2 titers than  
MF59 emulsion alone. The current results demonstrate  
that combinations of PE/GS liposomes with 2x MF59 do  
not perform as well as PE/GS liposomes combined with  
MF79/5% 1501. PE/GS liposomes do improve the perfor-  
mance of 2x MF59. PE/GS liposomes alone give very  
poor anti-gD2 antibody response. Combination of  
PC/PS liposomes with MF79/5% 1501 perform equivalently  
to PE/GS liposomes combined with MF79/5% 1501 (mean  
titer after three immunizations of 6946 vs. 4653).



TABLE 5  
GD2 Adjuvant Study in Goats

Number Animals	Adjuvant	Prebleed	Bleed 2/13a	Bleed 3/14a	Bleed 3/90	Bleed 4/7	Bleed 4/21	Bleed 4/42
5	MF79/L121	<5	888±179	2,582±948	60±28	3,782±917	2,267±692	492±196
5	MF79/L121 + Liposomes B (100*)	<5	1,418±391	6,884±1,274	115±51	6,229±1,544	7,987±1,250	1,241±345
5	MF79/L121 + Liposomes B (100*)	<5	784±628	13,449±1,908	-	-	-	-
5	MF79/L121 + Liposomes B (50/50* + WTP)	<5	945±609	4,563±2,563	-	-	-	-
5	Liposomes C (50/50* + WTP)	6±1	<5	9±2	19±5	<5	6±1	12±5
5	MF79/L1501 + Liposomes A (50/50*)	<5	2,068±268	7,864±1,253	-	-	-	-

a geometric mean + standard error.  
b immunization No/days past immunization; WTP-PE at 100 mg/dose.  
c GD2 antigen at 25 mg/dose.  
\* incorporation ratio of GD2 and/or WTP in liposomes.

Example 13: Effects of gB2 Association with Liposomes  
on the Immunogenicity of Liposome/Emulsion  
Combinations in Goats

5 In this experiment, goats were immunized three  
times at four week intervals with 5, 25, or 100  $\mu$ g of  
gB2 and 100  $\mu$ g of MTP-PE with one of the following  
adjuvants: 1, MF79/121, as defined in Example 12;  
2, MF79/121 combined with LPE (PE/GS/CHOL (8:2:2) FTF  
liposomes) such that 50% of the gB2 was associated  
10 with the liposomes and 50% was free in solution;  
3, MF79/L121 combined with LPE such that 100% of the  
gB2 was associated with the liposomes.

The effects of antigen association with liposomes  
for the 25  $\mu$ g gB2 dose groups are shown in Figure 2.  
15 Again, immunogenicity increases with increases in  
antigen association with liposomes. The geometric  
mean antibody titers  $\pm$  standard error for each group  
of animals are given in Table 6.

TABLE 6

Group	Ag Association <sup>b</sup>	Number of Animals	Adjuvanta	Prebleed Mean	Bleed 1/14 Mean	Bleed 2/14 Mean	Bleed 3/14 Mean
1	--	5	MF79/L121-MTP (5mg GB2)	<5	1,678±473	29,656±3,218	33,325±3,100
2	0	5	MF79/L121-MTP (25mg GB2)	<5	434±129	18,609±3,962	44,846±5,203
3	--	5	MF79/L121-MTP (100mg GB2)	<5	412±131	35,161±4,959	42,228±7,585
4	--	5	MF79/L121-MTP +Liposomes (A) (5mg GB2)	<5	1,666±413	17,565±3,610	36,700±6,230
5	100	5	MF79/L121-MTP +Liposomes (A) (25mg GB2)	<5	5,096±1,716	47,285±10,173	73,109±13,199
6	--	5	MF79/L121-MTP +Liposomes (A) (100mg GB2)	<5	1,289±422	38,544±6,263	59,493±13,706
7	50/50	5	MF79/L121-MTP +Liposomes (B) (25mg GB2)	<5	1,733±844	32,835±12,628	39,746±14,871
8	--	5	Liposomes (C) MTP* MF79/L121-MTP (25mg GB2)	<5	152±85	12,022±3,825	25,163±3,044

\* = 1st boost with Liposomes  
2nd and 3rd with MF79/L121  
a All MTP-PE doses are at 100mg/dose.  
b Ag association is shown only for the composition that appear in Figure 2:  
0 = GB2 free in aqueous phase;  
100 = GB2 all associated with liposomes; and  
50/50 = GB2 associated 50% with liposomes and 50% free in aqueous phase.

Example 14: Immunogenicity of Liposome/Emulsion  
Combination Using gp120 in Rhesus Monkeys

5 In this experiment, groups of 3 rhesus monkeys  
were immunized 3 times at 4-week intervals and one  
time 14 weeks after the third immunization. Animals  
were bled every 2 weeks throughout the experiment.  
One group received MF79/1501 (10% squalene, 1% Tween  
80, 5% Tetronic 1501, 400 µg/ml MTP-PE) combined with  
10 LPE FTF liposomes containing gp120/SF2. The other two  
groups received either 2XMF59 (10% squalene, 1% Tween  
80, 1% Span 85, 400 µg/ml MTP-PE) or SAF emulsion  
(10% squalene, 5% Pluronic L121, 0.4% Tween 80,  
500 µg/ml MDP). Figure 3 illustrates that MF79/1501  
15 and liposomes produced consistently higher titers than  
the other 2 emulsion formulations. Table 7 lists both  
individual animal titers and mean titers for each  
group throughout the experiment.

TABLE 7

Summary of Individual Antibody Titers, Mean Antibody Titers Per Group  
+ Standard Error

Immunization	Time(wk)	bleed#	8428	8429	8430	gr1 X	gr1.0 +SE	8431
1	0	.0	1	1	1	1	0	1
2	2	.01	50	50	1	14	17	1
3	4	.02	70	50	50	56	6	50
4	6	.03	4300	5100	5600	4971	384	4900
5	8	.04	1500	1400	1800	1558	117	1600
6	10	.05	5218	4841	2925	4196	762	6746
7	12	.06	1442	1	649	714	365	1915
8	22	.07	117	75	109	100	14	142
9	24	.08	5574	6808	4093	5375	796	5397
10	26	.09	3335	3405	3368	3369	20	1768
8432	8433	gr2 X	gr2.0 +SE	8434	8435	8436	gp3 X	gp3.0 +SE
1	1	1	0	1	1	1	1	0
2	1	60	11	50	50	82	59	9
3	50	56	6	50	50	105	64	15
4	3900	5798	1681	6200	3700	6900	5409	1041
5	1200	2021	781	2700	1100	2300	1897	525
6	14162	11874	2843	5471	8869	14790	4712	1956
7	3880	4263	800	1569	2156	3014	2168	408
8	338	3164	88	165	119	221	263	29
9	8808	270	967	4372	3386	6459	4573	859
10	4683	6811	783	2471	1475	4886	2611	906
		2747						

WO 92/00081

Example 15: Effects of MTP-PE Association with  
Liposomes or Emulsion on the Immunogenicity of gD2  
Combination Formulations in Rabbits

5 Rabbits were immunized three times at four week  
intervals with 10  $\mu$ g gD2 and 100  $\mu$ g MTP-PE. The  
results of this experiment, up to two weeks after the  
second immunization are included here in Figure 4 and  
10 Table 8. Comparison of groups 2 and 3, Table 8,  
shows that again immunogenicity was enhanced by  
combining emulsion MF59 (5% squalene, 0.5% Tween 80,  
0.5% Span 85, 400  $\mu$ g/ml MTP-PE) with gD2 prepared with  
LPE. Including MTP-PE in the emulsion, group 3, or  
the liposomes, group 4, did not produce significant  
15 changes in immunogenicity. Group 6 was immunized once  
with LPE and then boosted 2 times with MF59. In  
group 7, the order was reversed, the animals first  
receiving an injection of MF59 followed by 2  
immunizations with LPE. Clearly, priming with  
20 emulsion and boosting with liposomes is more  
immunogenic than the converse. The earlier cited Goat  
gB2 experiment (example 13, Table 6, group 8) confirms  
poor response when the animals were primed with  
liposomes and boosted with emulsion.

TABLE 8

Rabbit/gD2 - MTP-PE Association

<u>Group</u>	<u>Bleed 1/2</u>	<u>Bleed 2/2</u>
1 - LPE with MTP-PE	468+191	12254+3517
2 - MF59	14418+2698	200764+32488
3 - MF59/LPE	20859+4508	307828+75470
4 - MF58/LPE with MTP-PE	15241+1203	202640+58941
5 - MF58/LPE	6330+903	68069+8127
6 - 1X LPE with MTP-PE 2X MF59	1140+160	72001+3741
7 - 1X MF59 2X LPE with MTP-PE	11272+3117	211980+25964

- 
- gD2 at 10 $\mu$ g/dose
  - MTP-PE at 100 $\mu$ g/dose; group 5 received no MTP-PE
  - 5 animals per group

Example 16: Effects of Emulsion/Liposome Combination  
on the Immunogenicity of Malaria Sera 1 in Aotus  
Monkeys

5 Aotus monkeys were immunized three times at four  
week intervals with 100 $\mu$ g of Sera 1. Eighty-four days  
after the first immunization, the animals were bled  
and challenged with the Honduras strain of Plasmodium  
falciparum. The monkeys were subsequently monitored  
for both disease and parasitemia.

10 Antibody titers on day 84 and later protection  
from disease are shown in Table 9. Group 1 received  
only Freund's adjuvant and no antigen. Group 2  
received Freund's adjuvant and Sera 1. Groups 3 and 4  
received Sera 1 and either MF59 or MF59 with LPE,  
15 respectively. The combination formulation produced a  
5-fold increase in Ab titers compared to emulsion  
alone. In both groups, one out of three animals was  
protected from disease. Figure 5 shows the  
corresponding cumulative parasitemia scores. The  
20 parasitemia scores for the combination group 4 were  
nearly 10-fold lower than for group 3, which received  
MF59.



TABLE 9

Panama SERA 1 Aotus Monkey Trial #2  
ELISA Titers of Aotus SERA 1 Antisera

	<u>Prebleed</u>	<u>Final Bleed Day of Challenge</u>	<u>Mean Titers</u>	<u>Protection</u>
Group 1	<10	92		
Control CFA/IFA	<10	88	87	0/3
	<10	81		
Group 2	<10	465,021		
Control CFA/IFA	<10	909,318	719,333	2/3
SERA 1	19	783,661		
Group 3	191	20,258		
SERA 1 MF59.2	336	13,718	31,200	1/3
	<10	59,625		
Group 4	13	141,295		
SERA 1	24	254,074	169266	1/3
Liposome/MF59.2	<10	112,430		

Group No.: (1) Control FCA/FIA  
 (2) SERA 1 FCA/FIA  
 (3) SERA 1 MF59.2  
 (4) SERA 1 Fusogenic Liposomes/MF59.2

Example 17: Immunogenicity of Emulsion/Liposome  
Combinations in a Mouse Influenza Challenge Model

This experiment was designed to test the efficacy of adjuvant formulations in a heterologous viral challenge. Mice were immunized two times at a four week interval with 9  $\mu$ g of HA antigen and 40  $\mu$ g MTP-PE. The animal groups are defined in Table 10. Group 1 received HA without adjuvant. Group 2 received MF59. Group 3 received one immunization with MF77 (10% squalene, 5% Pluronic L121, 1% Tween 80, 400  $\mu$ g/ml MTP-PE), followed by a second immunization with MF59. Group 4 received one immunization with a combination formulation containing MF77 lacking MTP-PE and LPE with MTP-PE, followed by a second immunization with MF58 and LPE with MTP-PE. Group 5 received LPE with MTP-PE. Group 6 was not immunized. The antibody titers in Table 10 are for day 55, just prior to viral challenge. The highest titers were obtained in Group 4 with the combination formulation. Figure 6 illustrates the relative Ab titers for all the groups. On day 56, the mice were challenged intranasally with influenza A/Hong Kongp/13/68 (H1N1). The animals were monitored daily for disease, and the daily survival record is shown in Table 11. The percentage survival 14 days after challenge is shown in the lower panel of Figure 6. The combination formulation had 100% survival, the next best group was MF77 with 90% survival. HA vaccine without adjuvant had 40% survival compared to a 30% survival rate for the unimmunized group.

TABLE 10  
Mouse/Influenza

<u>Group</u>	<u>HA A/Shanghai</u>
1 - HA only	259 $\pm$ 60
2 - MF59	7822 $\pm$ 514
3 - 1X MF77 1X MF59	28749 $\pm$ 3778
4 - 1X MF77 w/o MTP-PE + LPE + MTP-PE 1X MF58 + LPE + MTP-PE	44257 $\pm$ 5234
5 - LPE + MTP-PE	1579 $\pm$ 184
6 - No immunization	< 5

---

n = 10

MTP-PE dose = 40 $\mu$ g

HA = 9 $\mu$ g of Parke-Davis influenza vaccine containing  
30  $\mu$ g/ml each of: A/Taiwan/1/86, A/Shanghai/11/87,  
and B/Yamaguta/16/88

TABLE 11

Taiwan Immunization  
Hong Kong Challenge

Daily Record of Number of Surviving Animals Per Group

<u>Group</u>	<u>Day</u>	0	1	2	3	4	5	6	7	8	9	10	11	12	13
1 HA alone	10	10	10	10	10	10	9	7	5	5	4	4	4	4	4
2 MF59.1	10	10	10	10	10	10	10	9	7	6	4	4	4	4	4
3 MF77.1/MF59	10	10	10	10	10	10	10	10	10	9	9	9	9	9	9
4 MF77.1 + L <sub>1</sub> ps	10	10	10	10	10	10	10	10	10	10	10	10	10	10	10
5 MF59 + L <sub>1</sub> ps	10	10	10	10	10	10	10	10	8	7	7	7	6	6	6
6 Liposomes	10	10	10	10	10	10	10	8	3	3	3	3	3	3	3

Example 18: Stability of Liposome/Emulsion  
Combinations

5       To assess the physical stability of a mixture of  
emulsion particles and liposomes, we prepared PE/GS  
(8:2)/MTP-PE (PL/MTP-PE, 20:1) dialysis liposomes  
containing FITC-dextran. External FITC-dextran was  
removed by gel filtration and the liposomes were mixed  
10 with MF79/1501 (10% squalene/1% Tween 80/5% Tetronic  
1501/400 µg/ml MTP-PE). Observations by light  
microscopy indicated no aggregation or coalescence of  
either emulsion particles or liposomes. Structural  
integrity of the liposomes was further confirmed by  
15 observation of fluorescent spheres against a dark  
background. No change in appearance has occurred  
after 3 months storage at 4°C.

Example 19: Storage of Liposomes and Emulsions

20       In order for the liposomes containing the  
antigens (encapsulated or incorporated by surface  
adsorption or integration into bilayer) and emulsions  
as a combination to be viable pharmaceutical entities,  
stable storage conditions and storage forms are  
25 explored. Three different dosage forms are designed  
to enhance the stability of the adjuvants and  
antigens: 1) Liquid liposome suspension-emulsion  
combinations in two vials or single vial storable at  
2-8°C. 2) Frozen liposomes - emulsion combination in  
30 two separate vials or single vial storable at 5-10°C.  
3) Lyophilized liposomes - emulsion in two separate  
vials or single vial storable at 2-8°C or ambient  
temperature.

35       A slightly acidic pH ( $\geq 5.0 = \leq 7.0$  preferably 6.5)  
is chosen for these formulations to improve the  
stability of the lipid components and the protein  
antigens. Cryoprotectants (for lyophilizations and  
freezing) are selected from the following list of

sugars or polyhydroxylic compounds and amino acids: dextrose, mannitol, sorbitol, lactose, sucrose, trehalose, glycerol, dextran, maltose, maltodextrins, glycine, alanine, proline, arginine, and lysine. In  
5 some formulations, a combination of sugars and amino acids e.g. sucrose-mannitol (sucrose 5-8% w/v, mannitol 2.5-1% w/v); sucrose-glycine (sucrose 8% w/v, glycine 60 mm) are used. These excipients also served as tonicifiers, i.e., provided physiologic  
10 osmolality. Buffers are selected from a group consisting of phosphate (5-50mM); citrate; phosphate buffered saline (PBS); acetate; maleate; ascorbate; tromethamine; and similar buffers.

In the case of liposomes, the cryoprotectants and  
15 buffers are included in a) both the aqueous interior and exterior or b) added only externally. In the latter instance, any buffer or salt (e.g. NaCl) provided osmotic balance for the interior, and the external salt is removed by repeated centrifugation  
20 and washing. The liposomes are then suspended in the excipient mixture of this invention. Emulsions are typically prepared in water and suspended in the medium discussed above. In addition to the sugar/amino acid/buffer combinations, viscosity  
25 enhancers are also added to some formulations. It is generally believed that these polymeric substances coat the particles and prevent contact which otherwise would result in aggregation, fusion or coalescence. Polymers used include polyethylene  
30 glycol 300, 400, 1450, and 3150; polyvinyl pyrrolidone; dextran sulfate; carboxymethyl cellulose; hydroxyethylcellulose and alginic acid. Polyethylene glycol 1450 is preferred and included in a concentration of 1% (w/v) in the formulation (for a  
35 list of typical ingredients see Table 12).

Liposomes, in addition to the excipients listed above, also optimally contained 1 mole percent of vitamin E or dl  $\alpha$ -tocopherol as an antioxidant. This

protects the unsaturated fatty acid moieties in the surfactants from oxidation, which in turn could catalyze the antigen degradation. Liposomes thus formulated are mixed with emulsions in different ratios e.g. 1:10 to 10:1 (v/v) as discussed earlier, even though for convenience 1:1 (v/v) is preferred. This mixture contains adequate amounts of the antigens and the immunostimulant in a therapeutic dose.

10       A number of other techniques can be used to prepare the desired compositions. For example, Gauthier and Levinson (EP0211257) freeze-dried a phospholipid emulsion in a two step process: the first step comprised spray freezing i.e., spraying a  
15       pre-formed emulsion onto a chlorofluorocarbon or similar compatible solvent at  $\leq -20^{\circ}\text{C}$  and collecting the frozen particles (which already contained cryoprotectants) and in a second step lyophilizing the particles. The resultant powder or cake, which  
20       generally contained sugars in vast excess, rehydrated to generate oil-in-water emulsions with particle sizes in the range of 0.48-0.7 micron. This method is cumbersome, provides large emulsion drops which may not be useful for certain therapeutic applications,  
25       where, for example, one would expect the particles to reside at the site of injection and slowly drain into lymphatics or suitable anatomic sites. Thus, one aspect of the current invention is to generate small, submicron liposome ( $\leq 0.4\mu$ ) and emulsion particles in a  
30       suitable medium providing storage advantage such that the size could be maintained without further growth. Another aspect of the invention is to prepare lyophilized liposome/emulsion combinations that are readily reconstitutable to particles with a mean  
35       diameter  $\leq 0.4\mu$  suitable for intended applications as vaccines.

The following illustrates by way of example the different dosage forms of antigen-bearing

liposome/emulsion combinations as being useful as vaccines providing higher immunogenicity in the animals as demonstrated above.

5     1. Liquid antigen-bearing liposome/emulsion combination

      Liposomes are prepared in sucrose-citrate (10% w/v, 10mM) or any other combination of excipients discussed in this section with the antigen. Any unbound protein is removed by a suitable technique  
10    such as dialysis, diafiltration or centrifugation (preferably centrifugation). The liposomes are suspended in the medium containing the same excipients as the interior of the liposomes except the antigen. In another set of liposomes (though not preferred),  
15    the vesicles are prepared in saline (0.9% w/v) or PBS together with the antigens and, after washing to remove unbound protein the liposomes are suspended in the cryoprotectant/viscosity enhancer and buffer, e.g.  
20    sucrose, PEG 1450, or citrate. Emulsions which are typically processed by homogenization in water were adjusted to physiologic osmolality with the excipient combinations to match the liposomes. Equal volumes of the vesicles and emulsions are combined and stored in a refrigerator at 2-8°C. Analysis over time indicates  
25    no loss of liposomal contents and retention of size by both particles (liposomes and emulsions).

2. Frozen antigen-bearing liposomes/emulsion combination

      Liposomes (fusogenic or otherwise) are prepared  
30    in sucrose (8% w/v)/mannitol (1% w/v), phosphate 10mM/PEG 1450 (1% w/v) containing the protein antigen and extruded through a polycarbonate filter to reduce the average particle size to 0.1 - 0.4  $\mu$ . Excess antigen is removed by centrifugation, and pelleted  
35    vesicles are resuspended in the same buffer excipient mixture. The liposomes are then combined with the microfluidized emulsions ( $\leq 0.4\mu$ ) and frozen in a refrigerator to temperatures  $\leq -10^\circ\text{C}$ . After storage



overnight, the formulation is allowed to thaw slowly to ambient temperature. Alternatively, liposomes and emulsions are frozen separately, thawed, and mixed or liposomes at 2-8°C are mixed with emulsions treated by freeze-thaw and combined prior to administration in animals. Both particulate materials retain their physical integrity during the freeze-thaw cycle. They are thus expected to provide storage convenience for human administration by being stored in single-vial or two-vial packages. It is found that certain saccharides (e.g. mannitol, lactose) included as the sole cryoprotectants do not help preserve the physical structure of liposomes and emulsions. However, cryoprotectants such as glycerol (2-20% w/v, preferably 2%), proline (0.3M), arginine (0.3M), sucrose-mannitol (sucrose 8% w/v, mannitol 1% w/v), sucrose-gly or arginine (sucrose 8% w/v, glycine or arginine 60mM), mixtures of amino acids (proline, glycine, alanine; 100mM each) all provide adequate cryoprotection during the freeze-thaw process, suggesting the possible application in vaccine formulations. Liposomes containing antigens and excipients such as PBS, saline or phosphate in the interior and cryoprotectant/buffer/(viscosity enhancer) in the exterior phase could also be mixed with the emulsion in the same cryoprotectant combination for the intended application.

### 3. Lyophilized antigen-bearing liposomes/emulsion combinations

As a stable storage form, this combination is highly preferred because bulk water which could cause chemical instability to lipids and proteins is eliminated. In addition, carbohydrates and amino acids commonly used as cryoprotectants are good support media for microbial growth. The following is illustrative of the design used in lyophilizations to generate dried vaccine formulations.

Antigen-bearing liposomes suspended in suitable cryoprotectant/buffer/(viscosity enhancer) such as those listed in Table 12 are combined with microfluidized emulsions in the same medium and freeze dried at temperatures below the cake collapse temperature for that excipient combination for 24-72 hr. (preferably 24 hr.). In one embodiment, for example, containing sucrose 10% w/v, citrate 10mM, primary drying is initiated at -40°C and temperature gradually raised to -10°C under good vacuum (10-100 microns, preferably 50 microns). After the completion of the primary drying process, the shelf temperature is gradually raised to ambient temperature (10-20°C per hour) and left at this temperature and vacuum for an additional 2-10 hours (preferably 4 hours) or until the moisture level in the dried product is reduced to 1-3%. Another variant of this formula consists of drying liposomes and emulsions separately and mixing the reconstituted suspensions to provide the desired formulation. In either case, the lyophilized cakes have acceptable physical appearance and readily reconstitute to provide injectible vaccine formulations.

Lyophilized single- or two-vial formulations by virtue of the low water content have acceptable stabilities for the lipid components and the protein antigens. The formulations can be stored at 2-8°C or ambient temperatures.

TABLE 12

Combinations of Cryoprotectants and Viscosity  
Enhancers used in the Formulations<sup>+</sup>

Sucrose\* (10% w/v)

Sucrose (8% w/v), mannitol (1% w/v)

Dextrose (5% w/v)

Sucrose (9% w/v), PEG 400, 1450 or 3350 (1% w/v)

Sucrose (9% w/v), hydrolyzed gelatin (1% w/v)

Sucrose (9% w/v), gelatin (fish skin, bovine or  
porcine 1% w/v)

Sucrose (9% w/v), Povidone 10000 or 40000 (1% w/v)

Glycine, alanine or proline (0.3M pH  
6-6.5)

Sucrose 9% (w/v) carboxymethyl cellulose (1% w/v)  
glycerol (2-20% w/v)

---

+ In addition, phosphate or citrate buffer is used  
in 10mM concentration to provide stability to  
antigens.


\* Other sugars, such as lactose, trehalose,  
maltose, etc., are substituted in appropriate weight  
amounts to provide equivalent physiologic osmolality.

5 All publications and patent applications cited  
in this specification are herein incorporated by  
reference as if each individual publication or patent  
application were specifically and individually  
indicated to be incorporated by reference at the  
location where cited.

10 Although the foregoing invention has been  
described in some detail by way of illustration and  
example for purposes of clarity of understanding, it  
will be readily apparent to those of ordinary skill in  
the art in light of the teachings of this invention  
that certain changes and modifications may be made  
thereto without departing from the spirit or scope of  
15 the appended claims.

WHAT IS CLAIMED:

1. A vaccine composition, comprising:
  - (1) an immunostimulating amount of an antigenic substance contained within or located on the surface of liposomes; and
  - (2) an oil-in-water emulsion comprising a muramyl peptide and a metabolizable oil in a continuous phase surrounding said liposomes.
2. The composition of Claim 1, wherein said antigenic substance is also present in said continuous phase.
3. The composition of Claim 1, wherein said liposomes comprise fusogenic liposomes.
4. The composition of Claim 1, wherein said liposomes and said emulsion are present in a volume ratio of from 1:10 to 10:1.
5. The composition of Claim 1, wherein said liposomes and said emulsion are present as particles occupying substantially the same size distribution range.
6. The composition of Claim 4, wherein said particles are substantially all less than 1 micron in diameter.
7. The composition of Claim 1, wherein said muramyl peptide is a compound of the formula



wherein R is H or COCH<sub>3</sub>;

R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> independently represent H or a lipid moiety;

R<sub>4</sub> is hydrogen or alkyl;

X and Z independently represent an aminoacyl moiety selected from the group consisting of alanyl, valyl, leucyl, isoleucyl, α-aminobutyryl, threonyl,

methionyl, cysteinyl, glutamyl, isoglutamyl,  
glutaminy, isoglytaminy, aspartyl, phenylalanyl,  
tyrosyl, tryptophanyl, lysyl, ornithinyl, arginyl,  
histidyl, asparinginy, prolyl, hydroxypropyl, seryl,  
and glycy;

n is 0 or 1;

Y is -NHCHR<sup>5</sup>CH<sub>2</sub>CH<sub>2</sub>CO-, wherein R<sup>5</sup> represents an  
optionally esterified or amidated carboxyl group; and

L is OH, NR<sup>6</sup>R<sup>7</sup> where R<sup>6</sup> and R<sup>7</sup> independently  
represent H or a lower alkyl group, or a lipid moiety.

8. The composition of Claim 6, wherein said  
muramyl peptide is either a muramyl dipeptide or  
muramyl tripeptide.

9. The composition of Claim 7, wherein said  
muramyl peptide is selected from the group consisting  
of muramyl dipeptides and tripeptides linked to a  
phospholipid moiety through a hydroxyalkylamine  
moiety.

10. The composition of Claim 4, wherein said  
muramyl peptide is N-acetylmuramyl-L-alanyl-D-  
isoglutaminy-L-alanine-2-(1,2-dipalmitoyl-sn-glycero-  
3-(hydroxyphosphoryloxy))ethylamide.

11. The composition of Claim 5, wherein said oil  
is an animal oil.

12. The composition of Claim 6, wherein said oil  
is squalene.

13. The composition of Claim 7, wherein said  
composition further comprises an additional  
emulsifying agent.

14. The composition of Claim 8, wherein said  
composition comprises up to 15% by volume of said oil.

15. The composition of Claim 9, wherein said  
additional emulsifying agent is selected from the  
group consisting of sorbitan esters, polyoxyethylene  
sorbitan mono-, di-, or triesters, polyoxyethylene  
fatty acids, polyoxyethylene fatty acid ethers, and  
combinations thereof.

16. The composition of Claim 10, wherein said additional emulsifying agent is selected from the group of polyoxyethylene sorbitan 20 monooleate, Span 85 sorbitan trioleate, and combinations thereof.

5 17. The composition of Claim 11, wherein said composition comprises up to 2.5% by weight of said additional emulsifying agent.

18. The composition of Claim 1, wherein said antigenic substance is a viral particle or subunit.

10 19. The composition of Claim 1, wherein said antigenic substance is a virus molecular antigen.

20. The composition of Claim 14, wherein said antigenic substance is selected from the group of genetically engineered proteins consisting of HSV rgD2, HIV gp120, HIV RT6, HSV gB-2, malaria Sera 1, and influenza vaccine antigens.

21. A method of stimulating an immune response in a host animal, comprising:

20 administering a protective antigen to said animal in association with liposomes, wherein said liposomes and said antigen or antigens are administered in the presence of a continuous aqueous phase containing an oil-in-water emulsion, wherein said emulsion comprises a muramyl peptide and a  
25 metabolizable oil.

22. The method of Claim 1, wherein said antigenic substance is also present in said continuous phase.

30 23. The method of Claim 1, wherein said liposomes comprise fusogenic liposomes.


24. The method of Claim 1, wherein said liposomes and said emulsion are present in a volume ratio of from 1:10 to 10:1.

35 25. The method of Claim 1, wherein said liposomes and said emulsion are present as particles occupying substantially the same size distribution range.

26. The method of Claim 4, wherein said particles are substantially all less than 1 micron in diameter.

27. The method of Claim 16, wherein said muramyl peptide is a compound of the formula

(I)



wherein R is H or COCH<sub>3</sub>;

R<sub>1</sub>, R<sub>2</sub>, and R<sub>3</sub> independently represent H or a lipid moiety;

R<sub>4</sub> is hydrogen or alkyl;

X and Z independently represent an aminoacyl moiety selected from the group consisting of alanyl, valyl, leucyl, isoleucyl, α-aminobutyryl, threonyl, methionyl, cysteinyl, glutamyl, isoglytamyl, glutaminyl, isoglutaminyl, aspartyl, phenylalanyl, tyrosyl, tryptophanyl, lysyl, ornithinyl, arginyl, histidyl, asparaginyl, prolyl, hydroxypropyl, seryl, and glycyl;

n is 0 or 1;

Y is -NHCHR<sup>5</sup>CH<sub>2</sub>CH<sub>2</sub>CO-, wherein R<sup>5</sup> represents an optionally esterified or amidated carboxyl group; and

L is OH, NR<sup>6</sup>R<sup>7</sup> where R<sup>6</sup> and R<sup>7</sup> independently represent H or a lower alkyl group, or a lipid moiety.

28. The method of Claim 17, wherein said muramyl peptide is either a muramyl dipeptide or muramyl tripeptide or a mixture thereof.

29. The method of Claim 18, wherein said muramyl peptide comprises a member selected from the group consisting of muramyl dipeptides and tripeptides linked to a phospholipid moiety through a hydroxyalkylamine moiety.

30. The method of Claim 19, wherein said muramyl peptide is N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-



alanine-2-(1,2-dipalmitoyl-sn-glycero-3-(hydroxyphosphorloxy))ethylamide.

31. The method of Claim 20, wherein said oil is squalene.

5       32. The method of Claim 21, wherein said oil is squalene.

33. The method of Claim 22, wherein said continuous aqueous phase further comprises an additional emulsifying agent.

10       34. The method of Claim 23, wherein said additional emulsifying agent comprises a member selected from the group consisting of sorbitan esters, polyoxyethylene sorbitan mono-, di-, or triesters, polyoxyethylene fatty acids, polyoxyethylene fatty  
15       acid ethers, and combinations thereof.




FIG. 1




FIG. 2

SUBSTITUTE SHEET




FIG. 3

SUBSTITUTE SHEET




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B

SUBSTITUTE SHEET

# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US91/04532

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup> According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): A61K 31/74, 37/02, 37/10, 37/22, 39/02, 39/04, 39/12 U.S.Cl.: 424/78,88,450; 514/8, 18, 19														
<b>II. FIELDS SEARCHED</b> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Minimum Documentation Searched <sup>7</sup></div> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 30%; border: 1px solid black; padding: 5px;">Classification System</th> <th style="border: 1px solid black; padding: 5px;">Classification Symbols</th> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">U.S.Cl.:</td> <td style="border: 1px solid black; padding: 5px;">424/78,88,450; 514/8,18,19</td> </tr> </table> <div style="text-align: center; border-top: 1px solid black; border-bottom: 1px solid black;">Documentation Searched other than Minimum Documentation to the extent that such Documents are included in the Fields Searched <sup>8</sup></div> <p>APS, Medline, CAS, search terms: antigen, liposome, vaccine, muramyl, surfactant, emulsifier, GP120, HIV envelope protein, recombinant</p>			Classification System	Classification Symbols	U.S.Cl.:	424/78,88,450; 514/8,18,19								
Classification System	Classification Symbols													
U.S.Cl.:	424/78,88,450; 514/8,18,19													
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT <sup>9</sup></b> <table style="width: 100%; border-collapse: collapse;"> <tr> <th style="width: 10%; border: 1px solid black; padding: 5px;">Category <sup>9</sup></th> <th style="width: 70%; border: 1px solid black; padding: 5px;">Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup></th> <th style="width: 20%; border: 1px solid black; padding: 5px;">Relevant to Claim No. <sup>13</sup></th> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4,199,565 (Fullerton) 22 April 1980, See Examples 1-5.</td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-34</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4,396,630 (Riedl et al.) 02 August 1983, See Examples 1-9.</td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-34</td> </tr> <tr> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">Y</td> <td style="border: 1px solid black; padding: 5px;">US, A, 4,772,466 (Allison et al.) 20 September 1988, see abstract, Table 1.</td> <td style="border: 1px solid black; text-align: center; vertical-align: top; padding: 5px;">1-34</td> </tr> </table>			Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>	Y	US, A, 4,199,565 (Fullerton) 22 April 1980, See Examples 1-5.	1-34	Y	US, A, 4,396,630 (Riedl et al.) 02 August 1983, See Examples 1-9.	1-34	Y	US, A, 4,772,466 (Allison et al.) 20 September 1988, see abstract, Table 1.	1-34
Category <sup>9</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>												
Y	US, A, 4,199,565 (Fullerton) 22 April 1980, See Examples 1-5.	1-34												
Y	US, A, 4,396,630 (Riedl et al.) 02 August 1983, See Examples 1-9.	1-34												
Y	US, A, 4,772,466 (Allison et al.) 20 September 1988, see abstract, Table 1.	1-34												
<div style="display: flex; justify-content: space-between;"> <div style="width: 48%;"> <p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 48%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>														
<b>IV. CERTIFICATION</b> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%; border: 1px solid black; padding: 5px;">           Date of the Actual Completion of the International Search  <div style="border: 1px solid black; padding: 2px; display: inline-block;">05 September 1991</div> </td> <td style="width: 50%; border: 1px solid black; padding: 5px;">           Date of Mailing of this International Search Report  <div style="border: 1px solid black; padding: 2px; display: inline-block; font-weight: bold; font-size: 1.2em;">03 OCT 1991</div> </td> </tr> <tr> <td style="border: 1px solid black; padding: 5px;">           International Searching Authority  <div style="border: 1px solid black; padding: 2px; display: inline-block;">ISA/US</div> </td> <td style="border: 1px solid black; padding: 5px;">           Signature of Authorized Officer  <div style="text-align: center;">              Richard C. Ekstrom           </div> </td> </tr> </table>			Date of the Actual Completion of the International Search <div style="border: 1px solid black; padding: 2px; display: inline-block;">05 September 1991</div>	Date of Mailing of this International Search Report <div style="border: 1px solid black; padding: 2px; display: inline-block; font-weight: bold; font-size: 1.2em;">03 OCT 1991</div>	International Searching Authority <div style="border: 1px solid black; padding: 2px; display: inline-block;">ISA/US</div>	Signature of Authorized Officer <div style="text-align: center;">              Richard C. Ekstrom           </div>								
Date of the Actual Completion of the International Search <div style="border: 1px solid black; padding: 2px; display: inline-block;">05 September 1991</div>	Date of Mailing of this International Search Report <div style="border: 1px solid black; padding: 2px; display: inline-block; font-weight: bold; font-size: 1.2em;">03 OCT 1991</div>													
International Searching Authority <div style="border: 1px solid black; padding: 2px; display: inline-block;">ISA/US</div>	Signature of Authorized Officer <div style="text-align: center;">              Richard C. Ekstrom           </div>													

Form PCT/ISA210 (second sheet) (Rev.11-87)

## III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)

Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No
Y	The Journal of Immunology, Volume 141, No. 5, issued 01 September 1988, I. Sanchez-Pescador et al., "The effect of adjuvants on the efficacy of a recombinant herpes simplex virus glycoprotein vaccine", pages 1720-1727, see page 1721.	1-34
Y	The Journal of Infectious Diseases, Volume 160, No. 6, issued December 1989, K.P. Anderson et al., "Effect of dose and immunization schedule on immune response of baboons to recombinant glycoprotein 120 of HTV-1", pages 960-969, see abstract.	1-34

Form PCT/ISA/210 (annex sheet) (Rev.11-87)